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Chronic lung diseases are often complicated with pulmonary hypertension 
(PH). This can lead to disability and poor prognosis. Oxidative stress has been 
implicated in the development of PH and right ventricular hypertrophy (RVH). 
A possible new way to treat lung disease related pulmonary hypertension is 
allopurinol (a xanthine oxidase inhibitor) which decreases both uric acid and 
oxidative stress. We hypothesised that allopurinol could regress RVH in 
patients with pulmonary hypertension associated with chronic lung disease 
(PH-CLD). 
In a double-blind, randomised controlled clinical trial, 72 patients with PH-CLD 
(93% diagnosed with chronic obstructive pulmonary disease and 17% with 
interstitial lung disease) were randomised to receive either allopurinol 300 mg 
twice daily or placebo for twelve months. The primary outcome was the mean 
change in right ventricular mass (RVM) as assessed by cardiac magnetic 
resonance imaging (CMRI) at twelve months. The secondary outcomes  were 
the change in other cardiac parameters measured by CMRI, St George’s 
Respiratory Questionnaire, Short Form 36, spirometry and six-minute walk test 
(6MWT). 
The mean age was 71 years, the mean FEV1 was 60% with mean resting SaO2 
of 96%. After 12 months, there was no significant change in RVM. There were 
also no significant changes in other cardiac parameters measured on CMRI, 
quality of life questionnaires, spirometry and 6MWT. Post-hoc subgroup 
analysis showed that allopurinol reduced RVM (allopurinol -6.16 g vs placebo 
26 
 
0.75 g, p = 0.02) in COPD patients with more severe airflow limitation. Patients 
with higher NT-proBNP (> 489 pg/ml) had a greater improvement in left 
ventricular ejection fraction with allopurinol 5.12 vs placebo -1.62, p = 0.02. 
In summary, allopurinol had no overall impact but reduced RV mass in COPD 
patients with more severe airflow limitation. Further studies are warranted to 















1.1 Pulmonary hypertension 
Pulmonary hypertension (PH) is defined as an increase in mean pulmonary 
arterial pressure (MPAP) ≥ 25 mmHg at rest as assessed by right heart 
catheterisation.1  The normal MPAP at rest is 14 ± 3 mmHg, with an upper limit 
of normal of approximately 20 mmHg.  
In the UK, it has been reported that the prevalence of pulmonary hypertension 
is 97 cases per million with a female-male ratio of 1.8.1  
The diagnosis of PH requires initial high clinical suspicion based on symptoms 
and physical examination, and review of comprehensive set of investigations 










1.1.1 Classification of pulmonary hypertension 
The causes of PH have been classified according to their clinical presentation, 
pathological findings, haemodynamic characteristics and treatment strategy as 
mentioned below2: 
1. Pulmonary arterial hypertension (PAH) 
2. Pulmonary hypertension due to left heart disease  
3. Pulmonary hypertension due to lung diseases and/or hypoxia  
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear and/or multifactorial mechanisms 
 
Group 1 PAH includes a variety of possible causes of PH characterised by the 
same pattern of vascular remodelling and are most likely to respond to PAH-
specific therapy. The drugs approved to treat Group 1 PAH include 
phosphodiesterase-5 inhibitors, endothelin receptor antagonists, prostacyclin, 
calcium channel blockers and riociguat. 
Group 2 consists of PH due to left heart disease (PH-LDH). PH-LDH can 
complicate any left heart disorder such as valvular heart diseases and 
congenital defects. The guidelines recommend optimisation of the treatment 
of the underlying condition which includes repair of valvular heart disease 
when indicated and aggressive therapy for heart failure with reduced systolic 
function.1 
Group 3 represents PH associated with lung disease and/or hypoxia. This is 
discussed in more details in section 1.2. 
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Group 4 is a disease of obstructive pulmonary arterial remodelling as a 
consequence of major vessel thromboembolism. Pulmonary endarterectomy 
(PEA) is the treatment of choice for this group. Balloon pulmonary angioplasty 
is increasingly an option for patients not fit for PEA. 
Group 5 includes several disorders with multiple patho-aetiologies. The 
mechanisms of PH are poorly understood and may include pulmonary 
vasoconstriction, proliferative vasculopathy, extrinsic compression, intrinsic 



















1.1.2 Clinical presentation 
The symptoms of pulmonary hypertension are non-specific and are mainly 
related to progressive right ventricular (RV) dysfunction. The typical symptoms 
are induced by exertion and include shortness of breath, fatigue, weakness, 
angina and syncope. Less commonly patients complain of dry cough, exercise-
induced nausea and vomiting. Abdominal distension and ankle oedema 
develop as a consequence of progressive RV failure. Other symptoms that 
patients may suffer from as a result of mechanical complications of PH and of 
the abnormal distribution of blood flow in the pulmonary vascular bed are: 
• Haemoptysis related to rupture of hypertrophied bronchial arteries.  
• Hoarseness of voice caused by compression of left recurrent laryngeal 
nerve secondary to pulmonary arterial dilatation. 
• Wheeze caused by large airway compression. 
• Angina due to myocardial ischaemia caused by compression of left main 
coronary artery. 
The physical signs that may be present in PH include left parasternal heave, 
an accentuated pulmonary component of the second heart sound, a 
pansystolic murmur of tricuspid regurgitation and a diastolic murmur of 
pulmonary regurgitation. In advanced disease, there are signs of right sided 
heart failure such as elevated jugular venous pressure, hepatomegaly, ascites, 







The abnormalities seen on electrocardiogram (ECG) include P pulmonale, 
right axis deviation, RV hypertrophy, RV strain, right bundle branch block and 
QTc prolongation. Supraventricular arrhythmias (such as atrial flutter and atrial 
fibrillation) may occur in advanced disease.3 
 
 
Figure 1 - Right ventricular hypertrophy: right axis deviation, right ventricular 









Chest radiograph can be normal. The radiographic abnormalities that are 
associated with PH include central pulmonary arterial dilatation, loss of 
peripheral blood vessels, enlargement of right atrium and right ventricle. 
 
 
Figure 2 - Chest x-ray showing central pulmonary arterial dilatation 
 
 
Pulmonary function tests 
Patients with pulmonary hypertension have a decreased lung diffusion 
capacity for carbon monoxide (DLCO). Studies have show that very low DLCO 
(< 45% predicted) is associated with poor outcome.4 Pulmonary function tests 





Transthoracic echocardiography should always be performed when PH is 
suspected. The echocardiographics signs suggesting pulmonary hypertension 
are in table 1 below. 
Ventricles Pulmonary artery Inferior vena cava & 
Right atrium 
Right ventricle / left 
ventricle basal 
diameter ratio > 1.0 
Right ventricular 
outflow Dopper 
acceleration time < 105 
ms and/or midsystolic 
notching 
Inferior cava diameter 
> 21 mm with 
decreased inspiratory 
collapse (< 50% with a 





eccentricity index > 1.1 




regurgitation velocity > 
2.2 m/s 
Right atrial area (end-
systole) > 18 cm2 
 PA diameter > 25 mm  
 
Table 1 - Echocardiographic signs of pulmonary hypertension (adapted)1 
 
The systolic pulmonary artery pressure (SPAP) can be estimated by 
measuring the peak tricuspid regurgitation velocity (TRV) and the right atrial 







Cardiac magnetic resonance imaging  
Cardiac magnetic resonance imaging (CMRI) is the technique of choice and 
considered to be the gold standard for accurate and reproducible assessment 
of the RV size, morphology and function.5-7 It also allows the non-invasive 
assessment of blood flow, including stroke volume, cardiac output, pulmonary 
arterial distensibility and right ventricular mass (RVM).1  
Echocardiogram Cardiac Magnetic Resonance 
Imaging 
Strengths: 
• Easily accessible 
• Quick assessment 
• Non-invasive 
Strengths: 
• More reliable to measure 
ventricular volumes and function 
• Non-invasive 
Weaknesses: 
• Images dependent on patient’s 
body habitus 
• Useful for screening but cannot 
be used reliably for individual 
diagnosis of PH 
Weaknesses: 
• Not portable 
• Not suitable if patient suffering 
from claustrophobia 
• Patients with pacemakers and 
ferromagnetic appliances 
cannot be studied 
• Expensive to purchase, 
maintain and operate 
 
Table 2 - Strengths and weaknesses of echocardiogram and cardiac 
magnetic resonance imaging 
Echocardiography is recommended to be used as a screening tool when PH 
is suspected. However, cardiac MRI is the gold standard for assessing cardiac 





Right heart catheterisation 
Right heart catheterisation (RHC) is an invasive investigation which is 
performed to confirm the diagnosis of pulmonary arterial hypertension or 
chronic thromboembolic pulmonary hypertension. It allows the assessment of 
the severity of haemodynamic impairment as well as providing measurements 
to support treatment decisions. Cardiac catheterisation is usually performed 
after the completion of other investigations so that it can answer specific 
questions that may arise from previous investigations and avoid an 
unnecessary procedure. RHC is not recommended for suspected PH in 
















1.2 Pulmonary Hypertension due to lung diseases and/or hypoxia 
Pulmonary hypertension that develops due to lung diseases has been 
classified in group 3.2 Many lung diseases can lead to pulmonary hypertension 
(Figure 3). The most common lung diseases associated with PH are chronic 
obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and 
combined pulmonary fibrosis and emphysema. Mild pulmonary hypertension 
(MPAP 25-39 mm Hg) is common in both severe ILD and severe COPD.8 
However, severe PH (MPAP> 40 mm Hg) in lung disease is uncommon.9 The 
development of PH in any lung disease is accompanied by a deterioration of 
exercise capacity, worsening of hypoxaemia and shorter survival.10-12 The 
severity of PH is usually poorly associated with the severity of the underlying 
lung disease.13,14 The most common indicator for the presence of PH in 
patients with underlying lung disease is a disproportionally low DLCO. 13,14  
 





• Chronic obstructive pulmonary disease (COPD) 
• Interstitial lung disease (ILD) 
• Other pulmonary diseases with mixed restrictive and obstructive pattern 
• Sleep-disordered breathing 
• Alveolar hypoventilation disorders 
• Chronic exposure to high altitude 
• Developmental lung diseases 
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1.2.1 Chronic Obstructive Pulmonary Disease 
Chronic obstructive pulmonary disease (COPD) is a common condition 
characterised by persistent respiratory symptoms and airflow limitation. It is 
predicted to become the sixth leading cause of disability and the third 
commonest cause of death by 2020.15  
COPD is the collective term for chronic bronchitis (regular sputum production 
for three months or more in two consecutive years)16, emphysema (destruction 
of the lung parenchyma) and chronic obstructive airways disease. The risk 
factors that are associated with COPD are cigarette smoking, tobacco, 
marijuana17, indoor pollution18 from biomass cooking and heating, 
occupational exposures19 due to organic and inorganic dusts, chemical agents 
and fumes.  
Common symptoms in patients with COPD are chronic and progressive 
breathlessness, chronic cough, sputum production, wheezing, chest tightness 
and frequent chest infections. In severe disease, patients may suffer from 
fatigue, weight loss20 and anorexia. Airflow limitation on spirometry is the 
hallmark for the diagnosis of COPD and is defined as post-bronchodilator fixed 
ratio of FEV1/FVC less than 0.70.21  The severity of airflow limitation is 





GOLD stage FEV1 (% predicted) 
GOLD 1  80 
GOLD 2 50-79 
GOLD 3 30-49 
GOLD 4 < 30 
 
Table 3 - COPD GOLD stages21 
 
COPD is associated with many comorbidities, the most serious and prevalent 
being cardiovascular disease, lung cancer, osteoporosis, muscle weakness 
and cachexia.22 A large proportion of the morbidity and mortality in COPD is 
associated with cardiovascular complications.23 Mannino et al (2013)9 have 
shown in a pooled analysis of two large epidemiological studies – the 
Atherosclerosis Risk in Communities study10 and the Cardiovascular Health 
Study11 – including more than 20,000 adults, that the prevalence of 
cardiovascular disease in patients with COPD was 20-22% compared with 9% 
in people without COPD. Cardiovascular disease usually encompasses 
ischaemic heart disease, congestive heart failure, pulmonary vascular 
disease, coronary artery disease, peripheral vascular disease, and stroke and 





1.2.2 Pulmonary Hypertension in COPD 
COPD may be complicated by the development of pulmonary hypertension. 
The severity of pulmonary hypertension in COPD (PH-COPD) patients is 
usually mild14  and is closely associated with patient’s age and severity of 
airway obstruction24. The pulmonary arterial pressure progresses slowly over 
time in patients with COPD and with mild-moderate hypoxaemia.11 The 
average increase in pulmonary arterial pressure is <1 mm Hg per year.11,25  
Prevalence 
The true prevalence of PH-COPD is unknown as there are no large scale 
population based studies and because of selection bias in studies assessing 
hospitalised patients.26 In studies14,27 that have estimated the prevalence of 
PH, figures of between 30% and 90% have been obtained. 
Pathophysiology 
The pathogenesis of PH-COPD is poorly understood, complex and 
multifactorial.24,28,29 Chronic hypoxia, inflammation, pulmonary vasculature 
remodelling, endothelial dysfunction, loss of blood vessels, and changes in 
pulmonary vascular tone have been recognised as pathogenic mechanisms. 
These in turn contribute to increased pulmonary vascular resistance and 





Figure 4 - Complex interactions between pathogenic mechanisms which may 
lead to increased pulmonary vascular resistance in patients with COPD28 
Reprinted from J Heart Lung Transplant, 31(6), Wrobel JP, Thompson BR, Williams TJ. 
Mechanisms of pulmonary hypertension in chronic obstructive pulmonary disease: a 
pathophysiologic review, 557-64, Copyright (2012), with permission from Elsevier. 
 
Alveolar hypoxia plays a key role in the development of PH-COPD. Hypoxia 
causes acute hypoxic pulmonary vasoconstriction of small muscular 
pulmonary arteries30 and in the setting of global hypoxia this mechanism may 
substantially increase pulmonary vascular resistance31 (PVR). Additionally, 
chronic hypoxia contributes to pulmonary vascular remodeling, resulting in 
intimal thickening and neo-muscularisation of small pulmonary arterioles, 
which also raises PVR.32 Studies have shown that chronic hypoxia can cause 
endothelial dysfunction.24  
Endothelial dysfunction plays an integral role in mediating the structural 
changes in the pulmonary vasculature and is caused by the altered production 
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of various endothelial vasoactive mediators such as nitric oxide, prostacyclin, 
endothelin-1, serotonin and thromboxane.33 Endothelial dysfunction has been 
demonstrated in COPD subjects.34,35 It has been postulated that genetic 
polymorphisms, inflammation and mechanical factors are likely to play an 
important role in modulating the endothelial dysfunction observed in PH-
COPD.36 
Pulmonary vascular remodeling is the process of structural transformation 
within the pulmonary vessels. The pathologic changes identified in pulmonary 
vessels in patients with PH-COPD include variable medial hypertrophy, 
longitudinal muscle deposition, intimal hyperplasia, elastin and collagen 
deposition, muscularisation of pulmonary arterioles and in situ thrombosis.28 
These changes alter the pulmonary vascular responsiveness and contribute 
to the development of PH in COPD. 
There is speculation that systemic inflammation which is a component of 
COPD, may promote pulmonary vascular remodeling and endothelial 
dysfunction in patients with COPD.29  
Emphysematous destruction of the pulmonary vascular bed contributes to the 
elevation of pulmonary arterial pressure and is often listed among the 
pathophysiological mechanisms of PH-COPD.13,14 The proposed mechanism 
is the reduction in the pulmonary capillary cross-sectional area and the 
reduction pulmonary blood flow.37 
Dynamic lung hyperinflation in COPD may contribute to the development of 
PH through a combination of mechanisms including increased lung volume, 
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widened intrathoracic pressure swings, cardiac effects, altered gas exchange, 
pulmonary vascular remodeling and endothelial dysfunction.28 
Prognostic implications 
The presence of PH in COPD is an established important prognostic factor in 
COPD subjects.10,38 PH-COPD is associated with increased mortality10, 
increased hospitalisations38 and reduced exercise function39. Shino et al.27 
have demonstrated an inverse correlation between mean pulmonary artery 
pressure (MPAP) and/or pulmonary vascular resistance (PVR) and survival. 
The 5-year survival rate for COPD patients with MPAP > 25 mm Hg is only 
36%.10 PH is also a vital risk factor for hospitalisation caused by acute 
exacerbations of COPD.40  
 
Figure 5 - Survival curve according to level of pulmonary artery pressure in 
COPD at onset of LTOT use 
Reprinted from Chest, 107(5), Oswald-Mammosser M, Weitzenblum E, Quoix E et al. 
Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of 
pulmonary artery pressure, 1193-8, Copyright (1995), with permission from Elsevier. 
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1.2.3 Interstitial Lung Diseases 
Interstitial lung diseases (ILD), also known as diffuse parenchymal lung 
diseases (DPLD), are a heterogeneous group of diseases with common 
functional characteristics (restrictive physiology and impaired gas exchange) 
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ILD result from damage to the lung parenchyma by varying patterns of 
inflammation and fibrosis. Some categories of ILD are associated with 
occupational or environmental exposures and/or collagen vascular disease, 
granulomatous lung diseases and some have unknown cause (idiopathic 
interstitial pneumonias). 
The symptoms that are common in patients with ILD are chronic and 
progressive breathlessness, and chronic cough. Fine crackles and finger 
clubbing may be present on physical examination. High-resolution computed 
tomography of the thorax is an integral part of the evaluation of patients with 
ILD. Some patients may proceed to have surgical lung biopsy for firm 
clinicopathologic diagnosis which then allows the patients and the clinician to 














1.2.4 Pulmonary Hypertension in Interstitial Lung Diseases 
The development of pulmonary hypertension in the context of ILD is 
increasingly a major adverse factor in the natural history of ILD.43,44 The 
diagnosis of PH may be missed in ILD patients because the clinical symptoms 
of PH (dyspnoea, fatigue and exercise limitation) are also symptoms 
characteristics of ILD. Pulmonary hypertension in ILD (PH-ILD) is usually 
diagnosed when clinical signs of right heart failure develop.45 The degree of 
PH-ILD is most often mild-to-moderate (resting MPAP ⩾ 25 mm Hg, but < 35 
mm Hg).46 
Prevalence 
The prevalence of PH in various ILD varies widely according to diagnosis and 
severity of the lung impairment. The most common ILD associated with PH are 
sarcoidosis, connective tissue diseases (especially systemic sclerosis and 
rheumatoid arthritis) and idiopathic pulmonary fibrosis (IPF). In the pre-
transplant setting, PH is detected by RHC in 28-46% of patients suffering from 
fibrotic lung diseases (with majority from IPF).12,47 Higher percentages of PH 
are found in advanced IPF (30% to 50%) and end-stage IPF cases (> 60%).8,48 
Pathophysiology 
The pathophysiological mechanism underlying the development of PH-ILD is 
poorly understood and is still the subject of investigation.24 Similar to PH-
COPD, hypoxic pulmonary vasoconstriction and vascular remodelling are 
considered the major culprits for increased peripheral vascular resistance in 
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PH-ILD.24,44,45,49,50 However, other disease-specific mechanisms are likely also 
involved in the development of PH. Additional mechanisms underlying PH-ILD 
include the obliteration of the vascular bed by progressive parenchymal 
fibrosis, inflammatory response within the pulmonary vasculature specific to 
underlying disease, endothelial dysfunction (with reduced levels of nitric oxide 
and prostacyclins, and increased levels of endothelin-1 and thromboxanes), 
oxidative stress and growth factors.24,44,50-52 In addition, low operating lung 
volumes in ILD can also raise the pulmonary vascular resistance as terminal 
airways tend to collapse in low lung volumes, thereby aggravating alveolar 
hypoxia and propagating hypoxic pulmonary vasoconstriction.53,54 The 
complexity of the pathogenesis of PH-ILD is illustrated in figure below.  
 
Figure 7 - Potential common pathophysiological mechanisms of parenchymal 
and vascular remodelling in ILD and PH43 
Reproduced with permission of the © ERS 2018.  European Respiratory Journal Jun 2008, 31 
(6) 1357-1367; DOI: 10.1183/09031936.00171307 
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In idiopathic pulmonary fibrosis, epithelial damage has been shown to promote 
pulmonary vascular remodelling via release of mediators (TGF- and 
pulmonary vascular smooth muscle growth factor)55. Moreover, elevated 
concentration of endothelin-1, which is a potent pulmonary vasoconstrictor, 
has been detected in patients with IPF with and without associated PH.56,57 
Prognostic implications 
Pulmonary hypertension has been associated with reduced survival in patients 
with ILD (as illustrated in Figure 8).12,24,43 Hamada et al.58 have also 
demonstrated that the 5-year survival is reduced in patients with PH (16.7%) 
as compared to patients without (62.2%). 
 
Figure 8 - PAH as a predictor of survival in patients with IPF12 
Reprinted from Chest, 129(3), Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. 
Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic 




The presence of PH in ILD is related to decreased diffusion capacity and the 
need for oxygen supplementation. Relative to measures of pulmonary function 
and hypoxia, altered pulmonary haemodynamics have a greater impact on 
exercise limitation (as measured by 6-minute walk distance) in IPF patients 
with PH compared with IPF patients without PH who have equally severe 
restrictive lung physiology.48,59 
 
Figure 9 - Correlation of 6MWD with systolic pulmonary artery pressure 
Reprinted from Respiratory Medicine, 106(11), Minai OA, Santacruz JF, Alster JM, Budev MM, 
McCarthy K. Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary 







1.2.5 Similarities in pathophysiological mechanism of development of 
PH in COPD and ILD 
The possible mechanisms for the development of pulmonary hypertension in 
COPD and ILD have been described in detail in sections 1.2.2 and 1.2.4 
respectively. Although there are some differences in the pathophysiological 
mechanisms, there is a common theme of chronic hypoxia and increased 
oxidative stress involved in both chronic lung diseases. Increased oxidative 
stress has also a role in the underlying mechanism of ventricular hypertrophy. 












1.2.6 Therapeutic options 
The mainstay management of pulmonary hypertension associated with 
chronic lung diseases (PH-CLD) is the optimising of the treatment for the 
underlying lung disease. Currently, there is no specific therapy recommended 
for PH due to lung disease.1 The published experience with targeted PAH drug 
therapy is limited and so far there is no adequate evidence to suggest that 
PAH drugs result in improved symptoms or outcomes in patients with PH due 
to lung disease. Hence the use of drugs approved for PAH (group 1)2 is not 
recommended for patients with PH due to lung disease (group 3). 
Long-term oxygen therapy (LTOT) 
The NOTT trial and the MRC trial have shown that long-term oxygen therapy 
was associated with improved mortality in patients with COPD.60,61 Both trials 
and the study by Weitzenblum et al. (1985) demonstrated that the pulmonary 
arterial pressure rarely returns to  normal values.44,61 The NOTT trial showed 
a slight decrease in pulmonary vascular resistance and Weitzenblum et al. 
study showed a slight decrease in pulmonary arterial pressure in a high 
percentage of patients with severe COPD. In contrast,  the MRC trial showed 
no change in pulmonary arterial pressure.  
In summary, there is no evidence to explain why oxygen therapy improved 
mortality in these patients. It is thought that perhaps oxygen therapy nullifies 
some of the effects of chronic hypoxia in these chronic lung diseases but so 




Endogenous nitric oxide (NO) facilitates smooth muscle relaxation and 
decrease pulmonary vascular resistance. Inhaled NO can worsen gas 
exchange in patients with COPD because of impaired hypoxic regulation of the 
matching between ventilation and perfusion.62 Pulsed inhalation of mixed nitric 
oxide and oxygen, when compared to LTOT in stable COPD patients with PH, 
improved MPAP and PVR.24 Nitric oxide is not a recommended treatment for 
PH-CLD. 
Phosphodiesterase-5 Inhibitors 
 Inhibiting the enzyme phosphodiesterase-5 (PDE-5) increases the 
concentration of cyclic guanosine monophosphate (cGMP) in pulmonary 
arterial smooth muscle cells, thereby increasing NO stimulation, resulting in 
vasodilation.24 
Despite improving pulmonary haemodynamics at rest and during exercise63, 
sildenafil did not improve exercise tolerance in patients with PH-COPD 
undergoing pulmonary rehabilitation64. The main drawback of PDE-5 inhibitor 
therapies is the significant worsening impairment of arterial oxygenation due 
to inhibition of hypoxic vasoconstriction.63 Sildenafil did not have a beneficial 
effect on exercise capacity in patients with COPD and emphysema without 
pulmonary hypertension. Goudie et al (2014)65 demonstrated that using 
tadalafil did not improve exercise capacity or quality of life despite exerting 
pulmonary vasodilation in patients with PH-COPD. 
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There were mixed results in studies with patients with PH-ILD. Sildenafil 
caused preferential pulmonary vasodilation and improved gas exchange in 
patients with severe lung fibrosis and secondary PH in a small open-label 
study of 16 patients.66 Sildenafil also preserved 6MWD and improved the St 
George’s Respiratory Questionnaire (SGRQ) score compared with placebo in 
the subgroup of 22 patients with right ventricular dysfunction in a controlled 
trial of 180 patients with advanced IPF.67 The results from Collard et al (2007) 
small open-label study of 14 IPF patients with PH were promising. They 
demonstrated improvement in 6-minute walk distance (6MWD) by sildenafil.68 
However, STEP-IPF (Sildenafil Trial of Exercise Performance in Idiopathic 
Pulmonary Fibrosis) trial which followed Collard et al. trial68 and enrolled 180 
patients, demonstrated that sildenafil did not improve 6MWD in patients with 
advanced IPF.69  
Overall, there is still not enough evidence to support the use of 
phosphodiesterase-5 inhibitors as a treatment option for PH-CLD. 
Endothelin Receptor Antagonists 
Endothelin-1 (ET) is secreted from endothelial cells and is a powerful 
vasoconstrictor inducing calcium release from the sarcoplasmic reticulum and 
causing smooth muscle contraction.24 Bosentan is a non-selective endothelin 
receptor antagonist while ambrisentan and macitentan are selective 
endothelin receptor A antagonists. 
A small trial of 16 patients with PH-COPD reported improved exercise capacity 
upon treatment with bosentan.70 This was in contrast with the results of another 
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small randomised clinical trial (RCT) of 30 patients with PH-COPD which 
showed that bosentan did not improve exercise capacity, lung function and 
pulmonary arterial pressure but instead caused significant deterioration in 
hypoxaemia and quality of life.71 
Negative RCT results have already been reported in IPF for all three ET 
receptor antagonists. B-PHIT study72 demonstrated that bosentan did not 
improve invasive pulmonary haemodynamics, functional capacity or 
symptoms over 16 weeks in patients with PH associated with IPF. Similarly, 
BUILD-3 study73 reported that bosentan did not delay worsening of IPF or 
death and had no treatment effects on health-related quality of life or dyspnea. 
ARTEMIS-IPF (placebo-controlled study to evaluate safety and effectiveness 
of ambrisentan in idiopathic pulmonary fibrosis) was terminated because of an 
increased rate of disease progression and respiratory hospitalisation.74 This 
led to ambrisentan being contraindicated in IPF patients, regardless of the 
presence of pulmonary hypertension. It has been observed in the MUSIC 
(Macitentan USe in an Idiopathic pulmonary fibrosis Clinical study) trial that 
macitentan had no effects on pulmonary function tests or time to disease 
worsening or death for patients with IPF.75  







Prostacyclin is a vasodilator secreted from endothelial cells. Different forms of 
prostacyclins have been used in the treatment of patients with PH with varying 
success.24 
Cicletanine, a furopyridine-derative drug (shown to enhance production of 
endogeneous prostacycylin) has shown to significant decrease mean 
pulmonary artery pressure and total pulmonary resistance after three and 
twelve months of treatment  by inducing effective pulmonary vasodilatation in 
PH-COPD but no significant change in oxygenation.76 
Inhaled prostacyclin and iloprost caused marked pulmonary vasodilatation 
with maintenance of gas exchange and systemic arterial pressure but long-
term therapy resulted in unequivocal clinical improvement.77 
12-week treatment with parenteral treprostinil improved right heart 
haemodynamics and echocardiographic parameters in a small group of 
patients with pulmonary fibrosis with severe pulmonary hypertension (MPAP 
⩾35 mm Hg).78 Sufficient evidence is lacking on the long-term use of 
vasodilators such as inhaled prostanoids that may preferentially access the 
better ventilated/oxygenated areas of the fibrotic lung due to their 
advantageous mode of distribution.77  
With these mixed results, prostacyclins have not been recommended in the 
treatment for PH due to lung disease. 
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Calcium Channel Blockers 
The treatment with conventional vasodilators such as calcium channel 
blockers is not recommended because they may impair gas exchange due to 
the inhibition of hypoxic pulmonary vasoconstriction62,79 and because of their 
lack of efficacy after long-term use.8,80 Nifedipine dilates pulmonary vessels 
constricted by hypoxia, without deleterious effects on arterial oxygenation in 
patients with chronic airflow obstruction and acute respiratory failure.79 
Riociguat 
Riociguat is a stimulator of soluble guanylate cyclase, a molecule that binds to 
NO and stimulates cyclic guanosine monophosphate.  
The pilot study by Ghofrani et al.81 demonstrated that a single dose of riociguat 
significantly improved MPAP and PVR but no relevant change in lung function 
or gas exchange. In an open-label uncontrolled phase II trial of 22 patients with 
PH-ILD, oral riociguat decreased pulmonary and systemic vascular resistance, 
improved cardiac output and PVR but not MPAP after 12 weeks of treatment.82 
However, a recent randomised controlled trial (www.ClinicalTrials.gov: 
NCT02138825) of riociguat versus placebo in pulmonary hypertension due to 
IPF was discontinued prematurely due to increased rates of death and serious 
adverse effects in the riociguat study arm. 




1.3 Right ventricle 
The right ventricle (RV) is a thin-walled, compliant and low-pressure chamber. 
Compared to the left ventricle (LV), the RV is thinner and has a different shape, 
which reflects the low pressure in the pulmonary circulation and allows quick 
adaptation to changes in preload.83,84 The right coronary artery (RCA) provides 
blood supply to the RV free wall in both systole and diastole.84 
The primary role of the RV is to deliver all the blood it receives into the 
pulmonary circulation on a beat-to-beat basis without causing the right atrial 
pressure to rise.85 The RV pumps the same stroke volume as the LV with 
approximately 25% of the stroke work.83,84 The septum and the free wall 
contribute approximately equally to the right ventricular function. The RV 
contraction occurs by longitudinal shortening and occurs in a peristaltic fashion 
starting with inflow tract contraction and proceeding to RV mid-wall, then the 
RV outflow tract contraction.85 
The blood the RV receives is called the venous return and in steady state, it 
equals the cardiac output.85 The rate of venous return is a function of the 
pressure gradient for the flow back to the heart from the periphery and its 
resistance.  
The RV afterload is determined by the wall tension of the RV. Under normal 
conditions, the RV afterload is highly dependent on the distribution of blood 
flow in the lung, the degree of hyperinflation or increased alveolar pressure 
that may be present, and active increases in pulmonary vasomotor tone as 
may occur with inflammation and alveolar hypoxia.85 
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1.3.1 Right ventricle and pulmonary hypertension 
The adaptive process associated with chronic pulmonary hypertension have 
been extensively described (Figure 10). Chronic pulmonary hypertension 
induces right ventricular hypertrophy (RVH). Early in the process, the RVH 
initially develops in the pulmonary outflow tract because this is the last region 
of the contracting RV to see the increased pressures and this will have the 
highest wall stress. The RV adaptation to pulmonary hypertension proceeds 
from minimal outflow tract hypertrophy with normal right atrial pressure, to 
generalised RV hypertrophy with sustained elevated right atrial pressure, to 
end-stage dilated cardiomyopathy identical to end-stage LV failure.85 
 
 
Figure 10 - The right ventricle and its load in pulmonary hypertension86 
The challenge for the right ventricle in pulmonary hypertension is to remain 
coupled to its load.86 In the early phase of the disease, the coupling of the RV 
and its load is maintained by a 4- to 5-fold increase in contractility of RV. The 




an increase in wall thickness, as well as changes in muscle properties per se. 
By thickening the wall, the ventricle tends to normalise the wall stress. 
However, as the disease advances, the hypertrophic process is halted and 
stroke volume (SV) decreases. The only mechanism to preserve SV is then 
right ventricular dilation. In an attempt to maintain cardiac output (CO) with the 
decreasing SV, the heart rate increases. Thus, RV uncoupling will occur in 
advanced stages of disease and during exercise. Compared with LV 
adaptation until heart failure, the RV can remain coupled for the large increase 
in load. 
The ventricular response to load also affects the diastolic function.85 The 
hypertrophy itself makes the ventricle stiffer, but changes in muscle properties 
add to this effect. The right atrial (RA) pressure and volume can be considered 
as surrogate measures of RV stiffness but those measures are load 
dependent. Increasing diastolic stiffness is associated with poor prognosis.86 
When the RV hypertrophies and dilates, this may result in RV ischaemia 
because the RCA is unable to provide adequate blood flow to the increased 
RV muscle mass, which is caused in part by the reduced RCA to RV cavity 
pressure gradient in both systole and diastole.85,87,88 As the pulmonary 
hypertension progresses, there is increased oxygen consumption because of 




Although the initial RVH in response to pressure overload may be adaptive, it 
is also the seemingly initial step in remodelling process that is ultimately 
damaging, perhaps irreversibly so. 
1.3.2 Right ventricle in chronic obstructive pulmonary disease 
The classic view of the development of right ventricular hypertrophy in patients 
with chronic obstructive pulmonary disease (COPD) is that a reduction of 
pulmonary vascular bed and hypoxia-induced pulmonary vasoconstriction 
increase pulmonary vascular resistance, resulting in pulmonary hypertension.  
The pathophysiology of the RVH in COPD is more complex than simply 
pulmonary hypertension increasing RV afterload and RV mass. This is 
exemplified by presence of RVH in patients with COPD before pulmonary 
vascular abnormalities.89  Vonk-Noordegraaf et al89 also showed that the RVH 
was accompanied with decreased right ventricular end-diastolic volume 
(RVEDV) with preserved right ventricular systolic function. Studies of autopsy 
in COPD have demonstrated anatomic evidence of right ventricular (RV) 
hypertrophy in two-thirds of patients with chronic bronchitis90 and one-third of 
patients with emphysema25. A possible explanation is that these cardiac 
changes without pulmonary vascular abnormalities are due to intermittent 
increases in pulmonary artery pressure (PAP) that occur during exercise 
and/or sleep. Another explanation is that oxidative stress directly causes 
ventricular hypertrophy.91 
Lung hyperinflation is commonly seen in patients with COPD. This is the result 
of loss of elastic recoil combined with expiratory flow limitation, promoting 
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increased expiratory lung volume (or air trapping) and intrinsic positive end-
expiratory pressure.26 Hyperinflation also decreases the venous return, 
thereby further reducing the RV filling. 
1.3.3 Interstitial lung diseases 
Interstitial lung diseases are characterised by a diminished lung volume due 
to changes in the lung parenchyma. Similar to COPD, right ventricular 
hypertrophy in ILD is thought to be caused by pulmonary hypertension, which 
is the result of raised pulmonary vascular resistance due to hypoxic pulmonary 
vasoconstriction and vascular remodelling causing increased pulmonary 
vascular resistance. Additionally, it has been postulated that the stiff lung 
parenchyma may compromise the function of the right heart.92 The right 
ventricular diastolic filling is restricted by the anatomical restriction of the 
pleura and thorax, contributing to cardiac dysfunction.44 
1.3.4 Right ventricular failure 
The initial adaptive response of myocardial hypertrophy is followed by 
progressive contractile dysfunction. The right ventricle then dilates to allow for 
compensatory preload and to maintain stroke volume despite reduced 
fractional shortening.84 At some point, the RV is unable to adapt further to 
increased RV afterload and right ventricular failure (RVF) will occur.93  
However, RVF can be reversed.94 Gorter et al.95 have observed normalisation 
of biventricular morphology and function, emphasizing the reversibility of 
severe RV dysfunction, within several months after lung transplantation in 
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patients with pulmonary arterial hypertension. The RV remodelling (RV 
hypertrophy, RV dilation and LV septal bowing) due to chronic thromboembolic 
pulmonary hypertension has also shown to be reversed after pulmonary 
endarterectomy.96 
1.3.5 Left ventricular function 
Under normal conditions, the impact of the right ventricle on the left ventricular 
function is negligible. In pressure overloaded RV, the ventricular 
interdependency leads to LV dysfunction. This is caused by leftward septal 
bowing, hampering filling of the LV (parallel interaction) and by decreased 












1.4 Oxidative stress 
Oxidative stress (OS) arises as a result of the endogenous antioxidant 
defences being overwhelmed by the presence of reactive oxygen species.97 
The balance between ROS production and antioxidant defences determines 
the degree of oxidative stress. Many environmental stimuli (for examples: 
cytokines, ultraviolet radiation, chemotherapeutic agents, hyperthermia and 
growth factors) generate high levels of ROS that can perturb the normal redox 
balance and shift cells into a state of OS. 
1.4.1 Reactive oxygen species 
Reactive oxygen species (ROS) are radicals derived from oxygen. The 
sequential reduction of molecular oxygen (i.e sequential addition of electrons) 
leads to the formation of a group of reactive oxygen species (Figure 11) 
 
Figure 11 - Reactive oxygen species 
 
The generation of reactive oxygen species is essential to life and to maintain 
homeostasis.98 ROS are generated constantly in the mitochondria as part of 
normal aerobic life. Under normal metabolic, complex III (ubiquinone-
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cytochrome c reductase) is the main site for ROS production in the electron 
transport chain, in the mitochondria (Figure 12). 
 
Figure 12 - Basic pathway for generation of ROS99 
Reprinted from J Mol Cell Cardiol, 34(4), Battelli MG, Polito L, Bortolotti M,Bolognesi A, 
Oxidoreductase-Derived Reactive Species: Physiological and Pathological Effects, 379-88, 
Copyright (2002), with permission from Elsevier. 
 
ROS are formed as necessary intermediates in a variety of enzyme reactions. 
For example: ROS generation by phagocytic cells constitutes an essential host 
defence mechanism necessary to fight infection.98 
However, ROS can be toxic to cells as they possess an unpaired electron, 
which makes them highly reactive and thereby able to damage all 
macromolecules, including lipids, proteins and nucleic acids.  The mechanism 
of ROS cytotoxicity is attributed to peroxidation of membrane lipids, DNA 
damage and protein oxidation, which impair mitochondrial function and lead to 
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apoptosis.100 ROS have proinflammatory activity because they regulate 
endothelial functions, by both increasing the permeability of vascular lining and 
modulating the arteriolar tone.100 
The burden of ROS production is largely counteracted by an intricate 
antioxidant defence system that includes the enzymatic scavengers such as 
superoxide dismutases (SOD), catalase, thioredoxin (TRX) and glutathione 
peroxidase (GPX). Other non-enzymatic, low molecular mass molecules 
scavenging ROS include ascorbic acid (vitamin C), pyruvate, flavonoids, 
carotenoids and most importantly, glutathione. 
The xanthine oxidoreductase system, which is one of the enzymatic process 
involved in the production of reactive oxygen species, is being looked at in 










1.4.2 Xanthine oxidoreductase 
Xanthine oxidoreductase (XOR) is the rate-limiting enzyme in the last two 
steps of purine catabolism in man.100,101 XOR was first identified in milk in 1902 
and is a member of the molybdenum hydroxylase flavoprotein family. 102,103 
XOR exists in two interconvertible forms, xanthine dehydrogenase (XDH) and 
xanthine oxidase (XO). Both forms of the enzyme carry out similar reactions 
of purine catabolism but the mechanisms of action are different. The 
conversion may occur either irreversibly by limited proteolysis or reversibly by 
chemical or enzymatic oxidation of XDH thiol groups.102 
Gene, expression and regulation 
The gene encoding XOR is located on the short arm of chromosome 2 and 
comprises of 36 exons. XOR activity is expressed at very low levels and a 
variety of factors upregulate transcription: hypoxia 104-106, lipopolysaccharide 
107,108, interferon γ 109,110, interleukin-1 109,110, interleukin-6 111, tumour necrosis 
factor α 109, dexamethasone, cortisol and prolactin.100,103  
Hyperoxia has previously been shown to decrease XOR activity in cell culture 
and rat lungs 112,113, while hypoxia was shown to induce a gradual increase in 
XOR activity in endothelial cells 105,112.  The mechanism by which oxygen 
tension affects XOR expression appears to be complex and is not very well 





XOR is widely distributed throughout various organs including the liver, gut, 
lung, kidney, heart, brain and plasma.114 Based on its levels of messenger 
RNA and protein expression, the highest activity levels of XOR are present in 
liver, intestine, kidney and lactating mammary gland epithelial cells and in 
vascular endothelial cells.100  
XOR has been detected not only in the cytoplasm of cells but also on the outer 
surface of the endothelial cell plasma membrane.102,103,115 XOR can be 
released into the systemic circulation from the liver and intestine during 
reperfusion after ischaemia.102 
Physiological functions 
XOR is the terminal enzyme of purine catabolism in man, catalysing the 
hydroxylation of hypoxanthine to xanthine and of xanthine to urate (Figure 
13).101  
Both XDH and XO catalyse the oxidation of hypoxanthine to xanthine and 
xanthine to uric acid but their mechanisms of action are different. XDH reduces 
NAD+ by a direct two-electron reduction while XO reduces molecular oxygen 





Figure 13 - Purine degradation pathway114 





XDH requires NAD+ as an electron acceptor to reduce hypoxanthine to 
xanthine (or xanthine to urate), thereby generating the stable reaction product 
NADH. XO is unable to use NAD+ as an electron acceptor, requiring instead 
the reduction of molecular oxygen for this purine oxidation, thereby generating 
the highly reactive superoxide free radical (O2-) and hydrogen peroxide 
(H2O2).116 
Pathophysiology role 
It is well established that XOR can act as a source of superoxide and hydrogen 
peroxide, which could exert protective (e.g bactericidal) or destructive effects. 
H2O2 generated by XO are dependent upon oxygen (O2) tension, pH and 
purine concentration. Under relatively physiologic conditions (21% O2 and pH 
7.0) XO catalyzes the reduction of O2 to H2O2 and O2.- at a ratio of 4:1 or ~80% 
H2O2 and ~20% O2.-.117  
H2O2 formation is further favoured when both O2 levels and pH are reduced.100 
Kelley et al.117 data confirmed an oxygen dependence of ROS formation in that 
lower oxygen concentrations lead to even greater H2O2 formation by XO. This 
is critical to note as hypoxia / inflammation leads to lower O2 tensions, 
increased XO expression, and increased hypoxanthine / xanthine levels from 
ATP catabolism and thus sets the stage for enhanced vascular H2O2 





1.4.3 Oxidative stress in the lungs 
The lungs are constantly exposed to sources of endogenous oxidative stress 
generated by mitochondrial respiration and inflammatory responses to 
bacterial and viral infections within the lungs.97 In the lungs, the endothelial 
cells, neutrophils, eosinophils, alveolar macrophages and alveolar epithelial 
cells are all major sites of ROS generation.118 Other sources of intracellular 
ROS include NADPH oxidase, the xanthine/xanthine oxidase system and the 
heme peroxidases.  
Elevated levels of ROS have been found in COPD and these may be 
associated with increased inflammation, airway remodelling, autoimmunity 
and corticosteroid resistance.97 Based upon a large number of studies in 
animal models, the three major stimuli that drive the vascular remodelling 
process via ROS in pulmonary hypertension are inflammation, shear stress 




Figure 14 - Schematic view of pathology of pulmonary hypertension118 
Reprinted from Compr Physiol, 3(3), Aggarwal S, Gross CM, Sharma S, Fineman JR, Black 
SM. Reactive oxygen species in pulmonary vascular remodelling, 1011-34, Copyright (2013), 
with permission from John Wiley and Sons. 
In the endothelial cells, ROS promote endothelial proliferation, decrease nitric 
oxide (NO) and increase the release of vasoactive mediators, leading to 
endothelial dysfunction. In smooth muscles, OS caused by ROS induces 







1.4.4 Oxidative stress in cardiac hypertrophy and remodelling 
Cardiac hypertrophy occurs in the presence of chronic hypertension. It could 
be a direct effect from chronic overload state (as discussed in section 1.3.1) 
but it could also be due to a direct effect of oxidative stress on the heart. 
ROS can be formed in the heart by a variety of mechanisms, including 
generation during oxidative phosphorylation in the mitochondria as a 
byproduct of normal cellular aerobic metabolism.119 Superoxide (O2-) is formed 
intracellularly by activation of nicotinamide-adenine dinucleotide phosphate 
(NADPH) oxidase or xanthine oxidase (XO), uncoupling of NO synthase (NOS) 
and electron transport and ‘leakage’ during oxidative phosphorylation in the 
mitochondria.120 Low levels of ROS are thought to play a role in normal cardiac 
signalling, growth adaptations and matrix changes. Higher levels play a role in 





Figure 15 - General schematic of generation pathways for ROS and 
antioxidant systems in the heart120.  
Reprinted from Hypertension, 49(2), Takimoto E, Kass DA. Role of oxidative stress in cardiac 
hypertrophy and remodelling, 241-8, Copyright (2007), with permission from Wolters Kluwer. 
Under conditions of afterload stress (pulmonary hypertension or systemic 
hypertension), both ventricles increase ROS production.121 Increased 
myocardial ROS levels might also reflect increased activity of intracellular 
oxidase complexes such as NADPH oxidase, xanthine oxidase or nitric oxide 
synthase. ROS have potent effects on the extracellular matrix, stimulating 
cardiac fibroblast proliferation, activating matrix metalloproteinase, effects 
central to fibrosis and matrix remodelling. ROS may mediate the hypertrophic 
response to well-recognised hypertrophic stimuli in redox sensitive pathways, 
such as mechanical strain, angiotensin, tumour necrosis factor- and -




Figure 16 - ROS mediated myocyte hypertrophy99 
Reprinted from J Mol Cell Cardiol, 34(4), Battelli MG, Polito L, Bortolotti M,Bolognesi A, 
Oxidoreductase-Derived Reactive Species: Physiological and Pathological Effects, 379-88, 
Copyright (2002), with permission from Elsevier. 
In the pulmonary hypertension-stressed right ventricle, the antioxidant 
enzymes superoxide dismutase and glutathione peroxidase are not activated 
at all in the compensate stage, predisposing the RV to ROS-induced damage 
at an earlier stage than in the LV.122 
Wang et al (2017) experimental study in rats have demonstrated that RV 






1.5 Uric acid 
Uric acid (interchangeably referred as urate) is the final product of purine 
nucleotides metabolism124. Uric acid (UA) is produced mainly in the liver and 
is excreted by the kidneys.  
Hyperuricaemia has been associated with increased risk of adverse 
cardiovascular outcomes in the general population.125 Several epidemiological 
studies have demonstrated a relation  between serum UA levels and a wide 
variety of cardiovascular conditions, including hypertension, metabolic 
syndrome, coronary artery disease, cerebrovascular disease, vascular 
dementia, pre-eclampsia and chronic kidney disease.126 This relationship is 
observed in frank hyperuricaemia (> 360 mol/L in women, >420 mol/L in 
men) and also in normal to high range (310 – 330 mol/L). Wei et al. (2010) 
cohort study of 7135 patients reported that high-dose ( 300mg) of allopurinol 
was associated with better control of urate level and lower risks of both 
cardiovascular events and mortality.127 
Serum and urinary UA levels are reported to be useful markers reflecting 
hypoxia in patients with various diseases such as obstructive sleep apnoea 
syndrome, chronic obstructive pulmonary disease, chronic heart failure, 
primary pulmonary hypertension, cyanotic congenital heart disease and 
Eisenmenger syndrome.128,129 Serum uric acid levels are elevated in patients 
with idiopathic pulmonary arterial hypertension (IPAH). 130 Increase in serum 
UA levels was proportional to clinical severity of IPAH and have a strong, 
independent association with long-term mortality of patients with IPAH.  
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Uric acid and its oxidized derivatives may exert pro-oxidant activity, mainly 
within the cell; however, it has in vivo antioxidant activity mainly in body 
fluids.100 
In summary, serum uric acid levels are elevated in hypoxic conditions such as 
chronic lung diseases (COPD and ILD). There is currently no evidence of any 
relationship between serum uric acid and pulmonary hypertension due to 
chronic lung diseases. 
The next section will discuss about allopurinol which is licensed and used for 

















Allopurinol (1,5-dihydro-4H -pyrazolo[3,4-d ]pyrimidin-4-one) is a potent 
xanthine oxidase inhibitor that was developed in the 1950s by Gertrude B. 
Elion and George H. Hitchings.114,131 The latter were awarded the 1988 Nobel 
Prize in Physiology and Medicine for its discovery.114  
 
Figure 17 - Structure of allopurinol 
 
Ellion and Hitchings have investigated several hundred purines, pyrimidines 
and analogues to increase the therapeutic efficacy of antineoplastic drugs 
such as mercaptopurine and its derivatives to discover new cancer 
treatments.114,132 Since mercaptopurine is known to be converted to inert 
thiouric acid by the versatile enzyme xanthine oxidase, the inhibition of the 
enzyme seemed to be one possible way of increasing the efficiency of this 
cytotoxic drug.131,133,134 Subsequently, allopurinol was found to decrease 
plasma concentration of urate and the occurrence of acute gout.134 
Since its Food and Drug Administration approval in 1966, it is commonly used 
worldwide for prophylactic treatment of gout134 and remains a cornerstone in 




Allouprinol is an analogue of hypoxanthine. Allopurinol is a very weak acid with 
acid dissociation constant (pKa) of 9.4 and is therefore essentially unionised 
at all physiological pH values. It has low lipid solubility as indicated by its 
octanol:water partition coefficient of 0.28. 
The active metabolite of allopurinol is oxypurinol, which is an analogue of 
xanthine. Oxypurinol is a somewhat stronger acid with a pKa of 7.7 and is 
therefore about 30% ionised in plasma (pH 7.4). Oxypurinol is more lipid 
soluble than allopurinol, with an octanol:water partition coefficient of 14. 
Oxypurinol should therefore pass more easily thorugh cell walls by passive 
diffusion. 
Both allopurinol and oxypurinol are inhibitors of xanthine oxidoreductase 
(XOR), which is the enzyme essential in the oxidation of hypoxanthine to 
xanthine, and xanthine to urate (section 1.4.2). As oxypurinol has a much 
longer half-life (t1/2) than allopurinol, it is largely responsible for the 
hypouricaemic effect of allopurinol. 
At relatively high concentrations (> 500 µM), allopurinol and oxypurinol have 
been shown to act as powerful scavengers of hydroxyl radicals in vitro and the 
possibility that the beneficial effects of these inhibitors could result from such 
scavenging have been examined.101 
Allopurinol by itself cannot prevent the generation of superoxide by XOR. It is 
an efficient alternative substrate of XOR that must first be converted to 
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oxypurinol, the actual inhibitor. Oxypurinol is referred to as a pseudo 
irreversible inhibitor that “inactivates” the enzyme. Allopurinol produces 
superoxide during its conversion to oxypurinol. The XO-catalyzed conversion 
of allopurinol to oxypurinol clearly generates superoxide during the reaction. 
In conclusion, allopurinol can generate superoxide during its conversion to 
oxypurinol as catalysed by XO. Moreover, although both allopurinol and 
oxypurinol are inhibitors of XOR that can block the formation of uric acid, only 
oxypurinol can inhibit the formation of superoxide.135 
1.6.3 Pharmacokinetics & pharmacodynamics 
Oral allopurinol is rapidly absorbed from the gastrointestinal tract. The oral 
bioavailability of unchanged allopurinol is quite high and estimated to be 79  
20%. The plasma concentration of allopurinol then declines rapidly with a 
mean t1/2 of 1.2 hours.  
After absorption, allopurinol is rapidly metabolised in the liver by oxidation to 
oxypurinol. The t1/2 of oxypurinol is much longer (23 hours) than that of 
allopurinol. Oxypurinol is the metabolite that accumulates in plasma during 
long-term dosing with allopurinol. During the long-term treatment, the steady-
state plasma concentrations of oxypurinol increase approximately linearly with 
the dose of allopurinol.  
Following a single dose of allopurinol, the plasma concentrations of urate fall 
slowly, reaching a maximal decrease between about 6 and 24 hours with little 
recovery over the next 2 days136,137. In healthy subjects, the t1/2 of urate is 
about 36 hours.138 Even at the highest plasma concentrations of oxypurinol, 
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the plasma concentrations of urate can be reduced by a maximum of 83% of 
the starting plasma concentrations. 
Approximately 10% of the oral dose of allopurinol is excreted unchanged in 
urine.131  The main route of elimination of allopurinol is via the oxidation to 
oxypurinol. The primary route of elimination of oxypurinol is by renal excretion. 
The clearance of oxypurinol is decreased in patients with renal 
impairment.139,140 Allopurinol elimination is not reduced with age as it is 
eliminated by metabolism. However, oxypurinol elimination is reduced in the 
elderly because of age-dependent decline in renal function.136 
1.6.4 Dosage 
Oxypurinol concentration at steady-state increases in a linear fashion over the 
dosage range of 50 to 600 mg/day of allopurinol132 (Table 3). Xanthine oxidase 
activity decreased with increasing steady-state plasma oxypurinol 
concentrations 
Allopurinol dose (mg/day) Steady-state oxypurinol concentration (mg/L) 
50 1.77  1.59 
100 2.67  1.59 
300 5.59  1.50 
600 9.56  1.92 
900 12.21  2.13 
 





Allopurinol should be introduced at low dosage (100 mg/day) to reduce the risk 
of adverse reactions and increased only if the serum urate response is 
unsatisfactory. Dosage schedules for gout are: 100-200 mg daily in mild 
conditions, 300-600 mg daily in moderately severe conditions, and 700-900 
mg daily in severe conditions. 
1.6.5 Side effects 
Allopurinol is generally a well-tolerated and has been used for over 50 years 
for the treatment of gout. The incident of true drug reaction was found to be 1-
2%.131 The side effects are usually mild gastrointestinal or hypersensitivity 
reactions.141 In a drug surveillance programme, the most common adverse 
effects attributed to allopurinol are skin reactions (1.8%), haematological 
abnormalities (0.6%), diarrhoea (0.3%) and drug fever (0.3%).142 The 
reactions were unrelated to age, weight, reason for therapy, blood urea or 
albumin concentrations. The reactions subsided within a few days after 
administration of the drug was suspended.131 Patients at higher risk of 
developing sensitivity reactions include those with chronic hyperuricemia, 
reduced renal function, advanced tophaceous gout, chronic alcoholism, and 
severe liver disease, and those being given thiazide diuretic therapy.131  
The most dangerous adverse reaction of allopurinol is toxic epidermal 
necrolysis (TEN).134 It is also called Stevens-Johnson syndrome or allopurinol 
hypersensitivity syndrome (AHS) or drug reaction with eosinophilia and 
systemic symptoms (DRESS syndrome).140 The patients develop a fever, 
exfoliative rash, lymphadenopathy, arthralgia, eosinophilia, vasculitis, hepatitis 
and deterioration in renal function, and it can be fatal141. The EuroSCAR143 
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study reported that allopurinol at daily doses of  200mg was associated with 
a higher risk of TEN (adjusted OR 36). The presence of HLA-B*5801 allele, 
which is a common allele in the Chinese population, is a very significant 
genetic risk factor for DRESS syndrome. All cases of the DRESS syndrome 
have occurred within two months of the commencement of dosage with 
allopurinol.134 
1.6.6 Allopurinol as antioxidant 
Several studies have looked into the potential benefits of XO inhibitors like 
allopurinol given the role of XOR in the production of ROS .141 
Coronary artery bypass surgery 
Giving allopurinol to patients who are scheduled to undergo coronary artery 
bypass surgery (CABG) has had mixed results.  
Johnson et al. (1991) demonstrated that pre-treating these patients with 
allopurinol (first dose given the evening before surgery and second dose at 4 
hours before scheduled surgery time) significantly improves cardiac function 
after surgery and is associated with lower hospital mortality rates. The hospital 
mortality rate was 4% in allopurinol group (n = 89) compared to 18% in placebo 
group (n = 80). These findings had let to a change in policy in their unit where 




When allopurinol was given both pre-op (300 mg twice daily for 2 days and 
600 mg on the morning of operation day) and post-op (300 mg twice daily for 
2 days), patients were at a lower risk of developing cardiac complications such 
as myocardial infarction (none in allopurinol group vs. 17.7% in control group) 
and arrhythmias needing treatment (6.6% in allopurinol group vs. 33.3% in 
control group; p < 0.01). The percentage of patients requiring inotropes or 
intra-aortic balloon pump post-operatively was significantly lower in the 
allopurinol group (4.4%) compared with the control group (26.6%).145  
In contrast, Taggart et al. (1994) and Coetzee et al. (1996) were not able to 
show that pre-treatment with allopurinol had a cardioprotective effect in 
patients with either good or impaired left ventricular function undergoing 
CABG. There were no significant difference in cardiac troponin T, CK-MB or 
myoglobin between allopurinol and control groups when measurements were 
done pre-op, subsequently at 1, 6, 24 and 72 hours post-op.146 When global 
left ventricular function was assessed, there was no difference in the left 
ventricular stroke work index before or after surgery in both allopurinol and 
control groups.147  
The differing nature of the cardiac operations (anaesthetic drug regime, degree 
of hypothermia) makes the interpretation of the results from the above four 
studies challenging. A possible explanation for the difference in the results is 
that none of the patients in Coetzee et al. (1996) study had beta-adrenergic 
blockers whereas there was no information whether patients in Johnson et al. 
(1991) and Rashid et al. (1991) studies had received any prior to arresting the 
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heart. It is known that beta-adrenergic blockers are cardioprotective and hence 
could have been a confounding factor.  
The population of Taggart et al. trial was smaller (n = 20) compared to Rashid 
et al. (n = 90) and Johnson et al. (n = 169). This could be a possible explanation 
for the negative result from Taggart et al. trial as the population size might have 
been too small to detect an effect. 
Endothelial function 
Endothelial dysfunction is a well established response to cardiovascular risk 
factors and precedes the development of atherosclerosis. It is characterised 
by reduction of the bioavailability of vasodilators and/or an increase in 
endothelium-derived contracting factors.148  
Several studies have demonstrated the benefits of allopurinol on endothelial 
function in a variety of conditions: cigarette smoking149, type 2 diabetes 
mellitus150, chronic kidney disease151, chronic heart failure152,153, chronic stable 
angina154 and obstructive sleep apnoea155. 
Cigarette smoking is well-known to cause endothelial dysfunction. By giving a 
single oral dose of 600mg of allopurinol to 14 cigarette smokers and comparing 
with age- and sex-matched healthy non-smoking control subjects, Guthikonda 
et al. (2003) have shown that allopurinol reversed endothelial dysfunction 
(assessed by forearm blood flow responses to intra-arterial administration of 
acetylcholine) in smokers without affecting responses in non-smokers.149 
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Butler et al. (2000) have suggested that free radicals could be an important 
and reversible cause of endothelial dysfunction in patients with type 2 diabetes 
mellitus. They have found that after giving 300 mg allopurinol for one month, 
the endothelial function, which was assessed by forearm venous-occlusion 
plethysmography (FVOP) with intra-arterial infusion of acetylcholine, was 
increased and that the level of malondialdehyde, which is an indirect measure 
of free radical activity, was also significantly reduced by allopurinol.150 
Improvement in endothelial function with allopurinol was confirmed in patients 
with chronic kidney disease (CKD). Kao et al. (2011) reported that endothelial 
function, assessed by flow-mediated dilation (FMD) of the brachial artery, and 
arterial stiffness, evaluated by pulse-wave analysis (PWA), were both 
improved after giving 9 months of allopurinol 300 mg/day to patients with 
CKD.151  
Farquharson et al. (2002)  found that allopurinol increased forearm blood flow 
response to acetylcholine with a reduction in plasma malondialdehyde level in 
their randomised, placebo-controlled, cross-over study on 11 patients with 
New York Heart Association (NYHA) class II-III chronic heart failure.152 This 
positive result in chronic heart failure was confirmed in two other small studies 
done by Doehner et al. (2002). The latter have demonstrated that allopurinol 
improved endothelial function, and the blood flow in the arms and the legs, 
along with a decreased allantoin level (another marker of oxygen free radical 
generation) in hyperuricaemic patients with chronic heart failure.153 
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High-dose allopurinol (600 mg/day) improved endothelial function (assessed 
by FVOP, FMD and PWA) of patients with stable chronic angina. Rajendra et 
al. (2011) also showed that vascular tissue oxidative stress was profoundly 
reduced.154 Based on these two findings, the authors allude the idea that 
allopurinol may reduce future cardiovascular mortality in stable coronary artery 
disease. This idea has been taken on board by Mackenzie et al. (2016) who 
are currently recruiting for the ALL-HEART study to investigate whether 
allopurinol improves cardiovascular outcomes in patients with ischaemic heart 
disease.156  
The severity of endothelial dysfunction correlated with the severity of sleep 
apnoea in El Solh et al. (2006) study.155 The other study findings were that 
allopurinol improved endothelial dysfunction and reduced plasma 
malondialdehyde levels in patients with moderate-to-severe obstructive sleep 
apnoea, who were given 300 mg allopurinol daily for 2 weeks. 
George et al. (2006) investigated the mechanism of action of allopurinol on 
endothelial function by comparing probenecid, which would only reduce urate 
level, versus placebo.  Their study confirmed that the mechanism of 
improvement in endothelial function with allopurinol lies in its ability to reduce 
vascular oxidative stress and not in urate reduction. They also found that 
increasing the dose of allopurinol from 300 mg to 600 mg improved the 





Chronic heart failure 
Ekelund et al. (1999) study has suggested that allopurinol can act as a novel 
inotropic agent that simultaneously decreases oxygen consumption and 
markedly increases myocardial mechanical efficiency in (pacing-induced) 
heart failure (in dogs).158 This idea was further supported by Cappola et al. 
(2001) study which has shown that XO activity may contribute to abnormal 
energy metabolism in human cardiomyopathy and short-term administration of 
allopurinol improves myocardial efficiency.159 Hirsch et al. (2012) further 
sustained the concept that allopurinol enhances the energetic profile of the 
failing human heart by increasing adenosine triphosphate (ATP) availability 
and increasing the amount of energy released with each ATP molecule 
hydrolysed.160 Opie (2012) proposed the potential sites of action of allopurinol 






Figure 18 - Proposed site of action of allopurinol in heart failure161 
Inhibition of xanthine oxidase by allopurinol brings with it decreased formation of cytosolic 
reactive oxidative stress which are increased in HF, leading to decreased inhibition imposed 
by ROS on CKc, which in turn stimulates the formation of cytosolic ATP from cytosolic PCr, 
thereby providing energy for contraction in HF.Reprinted from J Am Coll Cardiol, 59(9), Opie 
LH. Allopurinol for heart failure: novel mechanisms, 809-12, Copyright (2012), with permission 
from Elsevier. 
 
Struthers et al (2002) reported that high-dose allopurinol ( 300 mg/day) use 
was associated with reduced mortality and cardiovascular events in their 
retrospective cohort study of 1760 chronic heart failure patients.162 These 
findings were confirmed in a recent population-based cohort of 4785 heart 
failure patients.163 This study suggests that we have little understanding of the 
determinants of exercise capacity and quality of life in chronic heart failure. 
Farquharson et al (2002) raised the possibility that allopurinol could improve 
exercise capacity in patients with chronic heart failure after their study reported 
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an improvement in endothelial dysfunction with allopurinol.152 To answer this 
question, Gavin et al. (2005) gave three months of allopurinol 300 mg/day to 
50 patients with chronic heart failure (New York Heart Association class II and 
II). There was significant reduction in BNP with allopurinol but no significant 
difference in exercise performance as assessed by modified Bruce exercise 
tolerance test and six-minute walk test, no significant difference in high 
sensitive CRP, blood pressure and health-related quality of life 
questionnaire.164 
Shehab et al (2001) hypothesised that allopurinol-induced increases in nitric 
oxide bioactivity would be accompanied by favourable effects on resting heart 
rate variability or on spontaneous dysrhythmia counts in patients with chronic 
heart failure. The negative results from their small randomised, double-blind 
cross-over study of 16 patients with chronic heart failure did not support the 
hypothesis.165 
It is not surprising that more recent studies by Hare et al (2008) and Givertz et 
al (2015) showed that xanthine oxidase inhibition using oxypurinol or 
allopurinol did not improve symptoms in patients with chronic heart failure 
receiving optimal medical therapy.166,167 
The negative results from the above trials in chronic heart failure suggest that 
allopurinol is not helpful in the treatment of chronic heart failure. The reason 
for investigating allopurinol is its ability to decrease oxidative stress by 
reducing the production of reactive oxygen species by inhibiting xanthine 
oxidase. A possible explanation for the negative results is that the level of 
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oxidative stress in patients receiving optimal medical therapy for their chronic 
heart failure may not be at a high enough level to show any symptomatic 
benefit to patients when lowering it with xanthine oxidase inhibitors. 
Ischaemic heart disease 
Several studies have looked at whether allopurinol could have beneficial 
effects in patients with ischaemic heart disease. 
Rentoukas et al (2010) studied patients who had primary percutaneous 
coronary intervention (PCI) for acute ST elevation myocardial infarction 
(STEMI), at least 3 hours after the onset of symptoms. Allopurinol was 
administered as a loading dose 400 mg, followed by 100 mg for 1 month. The 
effects of allopurinol were more effective ST-elevation recovery, lower peak 
values of troponin I, creatine kinase (CK) and creatine kinase-MB (CK-MB). It 
was also noted that allopurinol improved clinical outcomes as a lower 
incidence of major cardiac events (cardiac death, non-fatal MI, repeat PCI, 
emergency CABG, sustained VT and intra-aortic balloon pump requirement) 
was present in the allopurinol group after  1 month follow-up.168 
Similar beneficial effects were noted using the same allopurinol regimen in the 
study by Separham et al (2016) who investigated 140 patients with acute 
STEMI and who were candidates for thrombolytic therapy. The authors 
reported that allopurinol was associated with better 90-minute ST resolution, 
lower enzymatically determined infarct size (lower levels of CK, CK-MB and 
cardiac troponin I) and in-hospital major adverse cardiac events.169 
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Allopurinol offered some beneficial effects in chronic stable angina. Noman et 
al (2010) found that allopurinol had anti-anginal effects in patients with chronic 
stable angina. They studied patients with chronic stable angina who were 
given 6 weeks of allopurinol (600 mg/day). The median time to ST depression, 
the total exercise time and the time to angina were all increased on exercise 
tolerance test (Bruce protocol for treadmill test). Anti-anginal effect with 
allopurinol prolongs exercise in stable chronic angina. It has been suggested 
that the mechanism underlying allopurinol anti-anginal effects is the increases 
in high-energy phosphates within ischaemic tissue and the reduction of 
oxidative stress.170  
Rajendra et al (2011) have shown that allopurinol profoundly reduces both 
vascular oxidative stress and endothelial dysfunction in coronary artery 
disease patients who are already taking optimal therapy.154 
The protective effect of allopurinol for the cardiovascular system is further 
reinforced by the population-based case-control study carried by de Abajo et 
al (2015). It demonstrated that allopurinol was associated with a reduced risk 
of non-fatal acute myocardial infarction (mainly apparent in men when exposed 
to doses of  300mg for more than 180 days).171 
The beneficial effects of allopurinol in ischaemic heart disease contrast with 
the negative results in the studies looking at chronic heart failure. A possible 
explanation for this is that not all chronic heart failure is due to ischaemic heart 
disease and in many cases, it can be due to a combination of two or more 
underlying cardiac diseases. It is understandably difficult to be absolutely 
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certain that every study participant’s diagnosis of chronic heart failure was due 
to only a particular cardiac disease. 
Patients with chronic heart failure and ischaemic heart disease could also have 
concomittant underlying chronic lung disease which would also have an effect 
on the heart. 
Left ventricular hypertrophy 
Left ventricular hypertrophy (LVH) is associated with many diseases and is 
claimed to be the strongest independent predictor of cardiovascular events, 
cardiovascular death and total mortality.172 Allopurinol has been shown to 
regress LVH  in patients with chronic kidney disease151 (CKD), ischaemic heart 
disease173 (IHD) and type 2 diabetes mellitus174 (DM) without change in blood 
pressure.  
Kao et al (2011) study involved 67 patients with CKD and LVH, who were 
randomised to allopurinol 300 mg/day or placebo for 9 months. They found 
that allopurinol reduced left ventricular mass index (LVMI) by -1.42 ± 4.67 g/m2 
compared to placebo. The changes in LVMI correlated with improvement in 
endothelial function, suggesting that the underlying mechanism of LVH 
reduction is linked to afterload reduction (which is the result of improvement in 
endothelial function).151 
Rekhraj et al (2013) had similar findings when they used higher dose of 
allopurinol (600 mg/day for 9 months) in patients with IHD and LVH. Allopurinol 
reduced LVMI by 2.2 ± 2.78 g/m2. The authors postulated that the LVH 
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regression was due to reduction in oxidative stress and improvement in 
endothelial function, hence a reduction in LV afterload.173 
In the same year, Szejkowski et al (2013) published the results of their study 
in patients with type 2 DM and LVH. Allopurinol (600 mg/day for 9 months) 
reduced LVMI by 1.32 ± 2.84 g/m2.174 
Hypoxia and respiratory diseases 
There has been an increasing interest in investigating the role of imbalance 
between oxidant and antioxidant factors, in particular the xanthine 
oxidoreductase system, in the pathogenesis of several respiratory diseases.175 
Several experimental studies have shown that allopurinol could be a possible 
new way to treat chronic lung diseases and pulmonary hypertension by 
inhibiting hypoxia-induced pulmonary vasoconstriction176, pulmonary 
hypertension176, endothelial dysfunction177, myocardial dysfunction178 and 
vascular remodeling179. 
XO activity was shown to be four times higher in sputum and bronchoalveolar 
lavage from patients with COPD compared with healthy subjects180 and there 
was a correlation between this activity and the severity of airflow obstruction181.  
Ichinose et al (2003) suggested that XO contributes to the production of 
reactive nitrogen species (RNS) in the airway, which have a role in the 
inflammatory process in COPD. They gave allopurinol (300 mg/day for 4 
weeks) to 10 COPD subjects and healthy subjects. They have demonstrated 
that reactive nitrogen species levels in the airway were elevated in COPD, and 
that administration of allopurinol decreased XO activity and increased exhaled 
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nitric oxide concentration, thereby reducing airway reactive nitrogen species 
production.182 Heunks et al (1999) reported the beneficial effects of allopurinol 
during strenuous exercise in patients with COPD. Exercise-induced oxidative 
stress was inhibited with allopurinol in this study of 16 COPD patients.183 
Unfortunately, there was no test in this study that was performed to check for 
evidence of pulmonary hypertension associated with COPD. 
XOR is recognised as an important effector in pulmonary vascular pathology. 
XOR-derived free radicals cause a dose-dependent contraction of rabbit 
pulmonary arterial rings.175 Terada et al (1992) study in cultured pulmonary 
artery endothelial cells showed that treatment with allopurinol inhibited the 
increased release of O2- from increased XO and XDH activity due to prolonged 
hypoxia.112 Hoshikawa et al (2001) demonstrated elevated lung XOR activity 
in a model of hypoxia-induced pulmonary hypertension in which the associated 
pulmonary hypertensive changes (pulmonary vascular thickening) were 
significantly attenuated by allopurinol.176 Jankov et al (2008) reported that, in 
the lungs of neonatal rats exposed to chronic hypoxia,  the vascular 
remodeling induced by XO-derived reactive oxyen species was prevented by 
treatment with allopurinol.179 Two more recent studies by Williams et al (2010) 
and Dopp et al (2011) have shown that allopurinol improved myocardial 
dysfunction178 and prevented the impairment of endothelial function in skeletal 





1.7 Rationale for study 
A possible new way to treat pulmonary hypertension associated with lung 
disease is allopurinol, which decreases both uric acid and oxidative stress. 
This possibility was mooted by Zharikov et al.184 but not yet explored. The case 
for allopurinol is based on several factors. Firstly and most importantly, there 
are five experimental studies all showing that allopurinol inhibits hypoxia 
induced pulmonary vasoconstriction, pulmonary hypertension, endothelial 
dysfunction and vascular remodelling.176-179,185 Secondly, hypoxia is known 
from many studies to up-regulate xanthine oxidase and therefore to increase 
its production of both uric acid and oxidative stress.112,176 Thirdly, there is one 
human study where allopurinol improved endothelial function in hypoxic 
patients.155 Fourthly, allopurinol profoundly reduces oxidative stress and OS is 
known to directly promote right ventricular hypertrophy as well as cause 
pulmonary vascular abnormalities.120 There is a fifth, albeit, fairly speculative 
further reason for studying allopurinol in lung disease. Allopurinol blocks XO 
enzyme which “wastes” molecular oxygen by converting it into oxygen free 
radicals. Therefore, in theory blocking this oxidase should boost tissue oxygen. 
There are clues that allopurinol might really boost oxygen come from animal 
studies where allopurinol reduces myocardial oxygen consumption and a 
human study where allopurinol reduced ischaemia during exercise in stable 
angina.158,159,170 
Therefore, there is a need to establish if allopurinol is beneficial in human lung 
disease in the same way as it has done in the experimental studies. 
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The hypothesis of this study is that allopurinol would reduce the production of 
reactive oxygen species, thereby decreasing oxidative stress, which would 
lead to regression of right ventricular hypertrophy in patients with pulmonary 
















2.1 Study Design 
2.1.1 Study Overview 
This is a single centre randomised, double-blind, placebo-controlled, parallel-
group study which was funded by the British Heart Foundation (reference: 
PG/14/6/30592). The study was approved by East of Scotland Research 
Ethics Committee on the 11th August 2014 (reference: 14/ES/1035), and by 
the Medicines and Healthcare products Regulatory Agency (MHRA) on 21st 
January 2015 (Eudract number: 2014-002305-38). The trial is registered on 
the International Standard Registered Clinical/social sTudy  Number (ISRCTN) 
registry (reference: ISRCTN11081180).  This study was carried out in 
accordance with the Declaration of Helsinki. The study was conducted 
between April 2015 and July 2017 at Ninewells hospital, Dundee, Scotland. All 
participants provided written informed consent after receiving a patient 
information sheet at least twenty-four hours before.  
2.1.2 Study Objectives 
The main aim of this study is to establish if allopurinol can regress right 
ventricular hypertrophy in patients with pulmonary hypertension associated 
with chronic obstructive pulmonary disease or interstitial lung disease. The 
study acronym is the ALPHA trial (does Allopurinol reduce right ventricuLar 
mass in Pulmonary Hypertension Associated with chronic lung disease). The 
secondary objectives were to assess the effect of allopurinol on cardiac size 
and function measured by magnetic resonance imaging (right ventricular end 
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diastolic volume, right ventricular end systolic volume, right ventricular ejection 
fraction, left ventricular mass, left ventricular end diastolic volume, left 
ventricular end systolic volume, left ventricular ejection fraction, pulmonary 
artery wave velocity), on exercise capacity as measured by six minute walk 
test (6MWT), on oxygen saturation pre and post 6MWT, on quality of life 
measures (St. George’s Respiratory Questionnaire, 36-Item Short Form 
survey, Transition Dyspnoea Index and King’s Brief Interstitial Lung Disease 
questionnaire), and on blood markers (N-terminal prohormone of brain 












2.2 Study population 
72 participants were recruited between April 2015 and July 2016. The inclusion 
and exclusion criteria used in the study are illustrated in Figure 19. 









• Male or female participants aged 18 years or over 
• Known diagnosis of chronic obstructive pulmonary disease or 
interstitial lung disease 
• Stable lung disease medication for at least two weeks prior to 
consent 
• Pulmonary acceleration time < 110 ms and/or right ventricular 
systolic pressure > 25 mm Hg and/or right ventricular free wall 
thickness ≥ 5.5 mm (on screening echocardiography) 
Exclusion criteria 
• Documented allergy or intolerance to allopurinol 
• Active gout (i.e flare up < 2 years) or currently taking allopurinol 
• Left ventricular ejection fraction < 45% on echocardiography 
• Severe aortic stenosis on echocardiography 
• Severe hepatic disease 
• Chronic kidney disease class 3B or greater 
• Patients taking azathioprine, 6-mercaptopurine, or theophylline 
• Malignancy (receiving active treatment) or other life-threatening 
diseases 
• Any contraindication to MRI (claustrophobia, metal implants) 






The participants were recruited from five separate sources identified as: 
1) NHS Tayside chest clinics 
2) The local clinical COPD database in Tayside  
3) The local respiratory research databases 
4) The general practices covering two UK National Health Service boards 
(Tayside and Fife) via the Scottish Primary Care Research Network 
(SPCRN) 
5) Scottish Health Research Register (SHARE) 
 
2.2.2 Scottish Primary Care Research Network 
SPCRN is the national primary care research network in Scotland and was 
established in 2002.186 It is funded by the Chief Scientist Office to facilitate high 
quality, funded, research studies. SPCRN was used to boost recruitment for 
the study within GP practices in Dundee, Angus and Fife. In the first instance, 
the SPCRN staff have sent an invitation email to general practitioners to ask if 
they would be interested to help with recruitment of the study. They then went 
to the GP surgeries who have agreed and they identified potentially eligible 
patients via the GP surgery computer database searches using the study 
eligible criteria. The list was then reviewed by one of the GP partners to 
exclude any unsuitable patients. SPCRN then helped to prepare the ethically 




2.2.3 Scottish Health Research Register 
SHARE is an initiative of NHS Research Scotland. It is a partnership between 
the National Health Service, the Scottish government and universities in 
Scotland to establish a Scottish register of people interested in participating in 
medical research.187  Patients who have signed up to the register, agree to 
allow SHARE to use the coded data in their various NHS computer records to 
check whether they might be suitable for health research studies. After doing 
NHS electronic database searches using coded data, staff from SHARE have 
contacted potentially eligible patients to ask them if they would be interested 
to participate in the study. If they were interested, their contact details would 











2.3 Study visits 
After they were recruited, the participants were enrolled in the study for a 
period of between 9 to 13 months. They attended for nine study visits including 
two telephone calls. A detailed study schedule is outlined in Figure 20.  
A screening visit was carried out for all participants to assess whether they 
fulfilled the entry criteria for the study. The participants were all consented prior 
to screening. At the screening visit, after informed consent, a medical history 
was taken and a clinical examination was performed. The participants then 
had an echocardiogram to check for evidence of pulmonary hypertension. 
Once the patients were known to be eligible, they had blood samples taken for 
safety analysis, and their vital signs, height and weight were measured. They 
also had a practice six minute walk test on the same day.  
They returned for the randomisation visit at any time up to four weeks after the 
initial screening visit. At the randomisation visit, they completed a six minute 
walk test, quality of life questionnaires and had their vital signs and pulmonary 
function tests measured. They also had their cardiac magnetic resonance 
imaging (CMRI) scan done on that day or within two weeks of this study visit. 
They were then randomly assigned to either placebo or allopurinol 100 mg. 
The participants were reviewed at two weeks, six weeks, three-month and 
nine-month. Safety blood tests were done, vital signs were measured, and 
compliance was checked and documented at each of the visits. The 
participants were advised on the importance of correct compliance if the 
compliance was poor, aiming for a compliance of above seventy percent. 
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Two telephone call visits were done at 8 weeks and 6-month. Any changes to 
their concomitant medications and any adverse events were followed up. The 
participants were reminded the importance of compliance. 
The participants continued all their usual medication, which remained 
unchanged throughout the study unless clinically indicated. When the 
participants were suffering from acute exacerbations of their respiratory 
condition (COPD or ILD), they were treated as per usual practice and the 
allopurinol or placebo was not stopped. 
A maximum of three out of nine visits (screening, randomisation and final 
visits) were done at Ninewells Hospital. The remaining study visits were 























Figure 20 - Study visits 
 
 
Visit 1 / Screening 
Consent 
History & examination 




Visit 2/ Baseline (Day 0) 
Randomisation 





CMRI (+/- 2 weeks) 
 
Visit 3 (2 weeks) 
Bloods 
BP, HR, RR, SaO2 
 
Visit 4 (6 weeks) 
Bloods 
BP, HR, RR, SaO2 
 
Visit 5 (8 weeks) 
Telephone call 
 
Visit 7 (Month 6) 
Telephone call 
 
Visit 6 (Month 3) 
Bloods 
BP, HR, RR, SaO2 
 
Visit 8 (Month 9) 
Bloods 
BP, HR, RR, SaO2 
 
Visit 9/ Final (Month 9-12) 





CMRI (+/- 2 weeks) 
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2.3.1 Safety blood tests 
Screening blood samples were taken for routine blood tests including full blood 
count (FBC), renal function (U&E), liver function (LFT), uric acid (UA), random 
blood glucose, haemoglobin A1C (if patient has a diagnosis of diabetes 
mellitus), lipid profile. These blood tests were repeated at final visit. Routine 
safety blood tests (FBC, U&E, LFT) were taken at regular visits throughout the 
study. The participants were reviewed at two weeks, six weeks, three month 
and nine month for these safety blood tests.  The safety blood samples were 
sent to and analysed by the Blood Sciences laboratory at Ninewells Hospital. 
2.3.2 Research blood tests 
Blood samples were taken at the screening visit and the final visit for research 
blood tests. Venous blood was drawn into ethylenediaminetetraacetic acid 
(EDTA) and serum blood bottles.  The EDTA bottles were immediately kept on 
ice and centrifuged as soon as possible for ten minutes at 3000 rpm at 40C 
(Heraeus Megafuge 1.0R, Kendro, Germany). The plasma was then pipetted 
into 5ml plastic aliquot bottles. The blood in the serum bottles was allowed to 
clot for fifteen minutes at room temperature before centrifuging for ten minutes 
at 3000 rpm at 40C. The serum was then pipetted into 5ml plastic aliquot 
bottles. Aliquot bottles for both serum and plasma were stored at -800C. An 
additional blood sample was taken from the participants and stored in a secure 
laboratory at -200C for future genetic research if the participants have 
previously agreed.  
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N-terminal prohormone of brain natriuretic peptide (NT-proBNP) was 
measured from plasma using a multi-array assay system (Meso Scale 
Discovery, USA). High-sensitivity troponin I (hs-Trop I) was measured from 
serum using a digital immunoassay on the SIMOA HD1-Analyser (Quanterix, 
USA). 
2.3.3 Echocardiography 
At the screening visit, the participant had a transthoracic echocardiography 
(echo) to assess if they fulfilled the criteria for pulmonary hypertension and to 
exclude impaired left ventricular systolic function and significant valve disease. 
The study was carried out using a Philips iE33 system (Philips, Netherlands) 
or a Philips Epiq7 ultrasound system (Philips Ultrasound, USA). If 
measurements were difficult to obtain using standard acoustic windows, we 
used the oblique subcostal windows188 to assess the pulmonary acceleration 
time with pulse-wave Doppler. The study protocol stated that patients were 
excluded if they had an estimated left ventricular ejection fraction of < 45%. 
For practical reasons, the technique of visual estimation was used to estimate 
LVEF rather than a quantitative measurement. We calculated the estimated 
mean pulmonary arterial pressure with the Dabestani equation189, and the right 
ventricular systolic pressure with the Bernoulli equation. 
2.3.4 Vital signs 
Vital signs were measured at each study visit.  
• Blood pressure (BP) was performed using an automated 
sphygmomanometer (Omron 705IT, Omron Healthcare Europe, The 
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Netherlands). All measurements were performed in a seated position 
with at least 10 minutes rest before the BP was recorded.  
• Resting peripheral oxygen saturation (SaO2) and heart rate (HR) were 
measured using a finger pulse oximeter (Merlin Medical Ltd, UK). 
• Respiratory rate (RR) was measured by counting the number of 
breaths over a minute. 
2.3.5 Spirometry 
Spirometry was performed by PLSC and LC using a Micro Medical Microloop 
spirometer (Viasys Healthcare, Micro Medical Limited, Kent) according to the 
ATS/ERS Task Force standardisation of spirometry document190. All patients 
were confirmed to have taken their usual inhaled therapy prior to performing 
spirometry.  Spirometry was done at the baseline visit and the final visit. 
2.3.6 Six Minute Walk Test 
Six minute walk tests were performed at the screening visit, the baseline visit 
and the final visit. On each of these occasions, the 6MWT was carried out on 
an even floor with vocal support from the investigator/delegate which is in full 
accord with ATS guidelines.191 The one done at the screening visit was a 
practice 6MWT and the one done at baseline visit was used for the baseline 
analysis. The 6MWT is fairly reproducible in lung disease with a correlation 
coefficient of 0·88.192 As is traditional and recommended for lung studies of the 
6MWT, the distance achieved was taken as the main result. Oxygen saturation 
(SaO2) was also measured during the 6MWT with a portable pulse oximeter 
(Merlin Medical Ltd, UK). Patients who were on long term oxygen therapy 
(LTOT) were included as there was no reason to believe that LTOT would alter 
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whether allopurinol works or not. It would be good to make this study relevant 
to all lung disease/PH patients so that any guideline advice that comes from 
this study will not only then apply to a subset of patients. The participants on 
LTOT had done their six minute walk test off oxygen (O2). This is because 
patients on LTOT spend nine hours every day off oxygen anyway and this is 
particularly likely when they are mobile. Therefore, by having them off O2 
during the 6MWT mimics how they would be when they try to become mobile. 
2.3.7 Quality of Life measures 
Quality of life (QOL) measures were carried out at baseline and final visits. The 
disease specific QOL measure which is used in COPD studies is the St 
George’s Respiratory Questionnaire (SGRQ). This is because it has been 
validated specifically in COPD patients: its subscales have reliabilities in the 
0·78-0·85 range 193 and it is responsive to change.194 The minimal important 
difference (MID) is a change of 4 units. The baseline (BDI) and transition (TDI) 
dyspnoea indices are commonly used methods to assess breathlessness and 
the impact of intervention.195 BDI was recorded at baseline visit and TDI at final 
visit. The TDI has a MID of 1 unit. 
It is traditional in QOL assessment to use both a general QOL measure and 
disease specific questionnaire in a study. For that reason this study also used 
the 36-Item Short Form Survey (SF-36). This is again for several reasons: it is 
the general QOL measure which is most used in COPD studies, it is reliable, 
it reflects disease severity and it is responsive.193,196-198 Only participants with 
ILD completed the King’s Brief Interstitial Lung Disease (K-BILD) QOL 
questionnaire which is a measure of health status for people with ILD.199,200 
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2.3.8 Cardiac Magnetic Resonance Imaging 
Cardiac magnetic resonance imaging (CMRI) was performed at the baseline 
and at the final visit only. MRI safety was established prior to the scan. This 
included: assessing for in vivo ferrous material, claustrophobia, abnormal renal 
function and pregnancy as per local NHS Radiology Safety Procedures. CMRI 
images were acquired on a 32 RF cardiac receiver channel, 3 Tesla MRI 
scanner (Prisma, Siemens, Erlangen, Germany) using dedicated phase array 
cardiac and phosphorous spectroscopy coils Serial contiguous short-axis 
cines were acquired from the vertical long axis and horizontal long axis of the 
left ventricle (electrocardiogram gated, steady-state free precession imaging 
[true fast imaging with steadystate precession], with the short axis imaging 
parameters being a repetition time of 2.5ms, echo time of 1.1ms, flip angle of 
60°, and slice thickness 6mm). The images were exported and the analysis 
was performed offline by a single independent, blinded radiologist (JWM) using 
CVI 42 (Circle Cardiovascular Imaging software, Calgary, Canada) for 
assessment of ventricular volumes (EDV, ESV, stroke volume), EF, and 
ventricular mass. Ventricular mass and volumes were also index to body 
surface area, which were calculated using the Mosteller formula.201 The 
reproducibility of the right ventricular mass assessment using MRI was derived 







After successful screening for eligibility and safety, the participants were 
randomised to either allopurinol or placebo in a double blind fashion. Double 
blind medication (allopurinol or placebo) were prepared, packaged and 
labelled by Tayside Pharmaceuticals.  
Randomisation were carried out by Tayside Pharmaceuticals using block 
randomisation in twelve groups of six (with three active/three placebo in each 
block). They used a validated randomisation program and had securely 
backed up both the randomisation seed and the randomisation allocation. A 
copy of the allocation was supplied with the allopurinol and placebo tablets to 
the Clinical Trials Pharmacy at Ninewells Hospital who operates a 24 hour 
emergency unblinding facility. 
2.4.1 Drug titration 
The participants were dosed with either allopurinol 100 mg or matched placebo 
at the randomisation visit. They were asked to take one tablet daily for two 
weeks. Thereafter, the medication was increased to 300 mg once daily or 
placebo and continued for four weeks. If the study drugs were tolerated, the 
dose was increased after this four week period to the target dose of 600 mg 
allopurinol/placebo (given as one 300 mg tablet twice daily) and continued for 
a further 7.5 to 10.5 months so that the participant was in the trial, on 
medication, for 9 to 12 months.  
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If there was any significant deterioration in the safety blood tests, the dose was 
then stopped and the participant did not receive any further IMP. If the 
participants had tolerated a lower dose (300 mg) and was experiencing side 
effects on the higher dose (600 mg), they were downtitrated back to the 300mg 
dose. If the participant was taken off the study, their GP and consultant was 
informed of the abnormal blood results or the reason for stopping the trial 
medication. If the trial medication was stopped, the participant remained in the 
study for the entire duration if they had agreed to it.  
2.4.2 Study drug 
The manufacture, packaging and labelling of the study drug was carried out by 
Tayside Pharmaceuticals, Ninewells Hospital, Dundee. Allopurinol was 
enclosed in a hard gelatine capsule shell. The placebo capsules had an 
identical appearance to the active drug and contained microcrystalline 
cellulose. Allopurinol/placebo capsules were included in packs containing the 
adequate number of units required for each treatment period. The study 
medication was stored under the supervision of the Clinical Trials Pharmacist 
at the Clinical Trials Pharmacy at Ninewells Hospital. The temperature logs 
were maintained throughout the study and were reviewed as part of the 
monitoring plan.  
2.4.3 Prohibited medications 
The concurrent prescription of 6-mercaptopurine, azathioprine or theophylline 
was not allowed due to the known interaction of these drugs with allopurinol. 
Any participants already on these drugs were excluded at the screening visit.  
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The use of ampicillin or amoxicillin was not prohibited. An increase in 
frequency of skin rash has been reported among patients receiving ampicillin 
or amoxicillin concurrently with allopurinol compared to patients who are not 
receiving both drugs. The cause of the reported association has not been 
established. However, in participants receiving allopurinol an alternative to 
ampicillin or amoxicillin was used where available. 
2.4.4 Emergency unblinding procedures 
A clinician familiar with the research was available each workday for contact 
by all participants. Any other clinician who saw the participants in the study 
was free to stop the study drug if they felt it was clinically indicated and they 
would have contacted the Clinical Trials Pharmacy Department at Ninewells 
Hospital to break the code if they felt it was necessary. Emergency unblinding 
was not needed throughout the duration of the study. 
2.4.5 Withdrawal procedures 
The participants were given the choice as to whether they withdrew or not from 
the study if they suffered side effects from the medication. Rash is known to 
be the main side effect and withdrawal would occur if it was marked as 
persistent. 
The participants who withdrew would be replaced if possible within the study 
timeframe. Those who withdrew from study drugs were encouraged to attend 
future study visits and where possible the final visit for outcome measures. 
PLSC maintained contact with those who withdrew to ensure resolution of 
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adverse event(s). The reasons for withdrawal were noted in the participant’s 
case report form (CRF) and case notes.  
The participants were free to withdraw from the study at any time. The reasons, 
















The study was conducted in accordance with the principles of Good Clinical 
Practice (GCP). The trial was monitored in accordance with TASC SOP 04 to 
ensure adherence to GCP.  
Patient contact was frequent during the trial (7 face-to-face visits and 2 
telephone calls) to ensure that there was no safety concern. At each patient 
contact, all reported adverse events were recorded in detail (dates, expected 
causation and action taken) on an adverse event (AE) CRF page. The 
seriousness of the AE was assessed by the principal investigator (PLSC) who 
would initiate the appropriate treatment if required. Events such as acute chest 
infections and increased dyspnoea were not recorded or reported as they are 
common events in this patient population. 
All AEs which were classified as serious adverse events (SAEs) were reported 
to the pharmacovigilance section of TASC 
(pharmacovigilance.tayside@nhs.net). PLSC completed a SAE report form for 
each one of them. He has assessed for expectedness and causality, based on 
the knowledge of the reaction and the relevant product information. 
All AEs and SAEs were recorded from the time a participant consents to join 
the study until their last study visit. The participants with unresolved AEs at the 
last study visit were followed up until resolution or 30 days after last study visit, 




2.6 Data collection & management 
The data was initially collected by PLSC and LC on a paper case report form 
(CRF). The CRFs were stored in a locked filling cabinets in a room with door 
locked out-of-hours. The access to the CRFs was only available to PLSC and 
LC. The data was subsequently transcribed to an electronic CRF on a web-
based freeware database (OpenClinica, USA).  
The data management system was provided by Tayside Clinical Trials Unit 
(TCTU) using OpenClinica (OC). The system was based on the study protocol 
and the CRF. The development and validation of the study database, the 
quality control and the extraction of the data were done according to TCTU 
procedures.  
The MRI data was stored on NHS Tayside Clinical Systems and was 
anonymised by a single blinded observer (JWM) before being analysed at end 








2.7 Statistics and data analysis 
2.7.1 Sample size calculation 
66 patients were required to achieve 80% power to detect a 5 g change in RV 
mass at a significance level of p < 0.05, based on previous studies 151,173,174 
investigating the allopurinol’s effect on (left) ventricular mass using CMRI. In 
order to allow for 10% drop-outs, 72 eligible patients were recruited.  
One review article suggests that the initial proof of concept study (like this) 
should only involve 30-40 patients.202 Another authoritative article from a 
leading expert in England suggests that 34 patients are required to have 80% 
power at p < 0·05 to detect changes in the manually measured outcomes of 
RV mass of 10 g.5 However, a 10 g change in ventricular mass was over 
ambitious. Sildenafil, which is an established treatment for PH, only reduces 
RV mass by 8 g in pulmonary arterial hypertension.203 
2.7.2 Statistical analysis 
The data for continuous outcome measures have be assessed for normality 
prior to analysis.  The descriptive statistics in form of mean ± standard 
deviation (SD) for normally distributed continuous variables, median and 
interquartile range (IQR) for non-normally distributed continuous variables, 
and percentages and denominators for categorical variables are tabulated at 
the baseline visit.  The comparison between continuous variables are analysed 
using paired t-tests (to test within group differences), independent t-test (to test 
between group differences), or Mann-Whitney U test (for non-normally 
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distributed data) whilst categorical variables were analysed using Chi-
squared test.  
All statistical analyses were undertaken blinded using IBM SPSS Statistics 
v22.0 (IBM, United States). A two-sided p value < 0.05 was considered 
statistically significant.  
2.7.3 Missing data 
The primary analysis was based on the intention-to-treat principle. The extent 
of missing data was examined and the reason for drop-out was ascertained. 
Multiple imputation was used to impute missing values and where assumptions 
for missing at random data were met. Complete case analysis where missing 


























3.1 Study Recruitment 
A total of 1914 invitation letters were sent from April 2015 to June 2016. 422 
(22%) replied that they were interested. After reviewing electronic medical 
records, 231 were excluded from invitation if eligibility criteria were not met or 
if patient declined after phoning them. A total of 191 participants were 
screened from April 2015 to July 2016. Recruitment was halted for six weeks 
from end of September to October 2015 due to the MRI machine being 
serviced and upgraded. 119 participants, out of 191 screened, were excluded 
because of the following reasons: 
•  91 participants did not meet the echo criteria for pulmonary 
hypertension 
• 17 participants were unable to undergo CMRI  
o Contraindications to MRI (n = 7) 
o Claustrophobia (n = 7) 
o Unable to tolerate MRI (n = 3) 
• 11 participants had other reasons: 
o Recent change of medication within two weeks of screening (n = 
2) 
o Already enrolled in another clinical trial (n = 2) 
o On theophylline (n = 1) 
o New diagnosis of lung cancer (n = 1) 
o Deranged liver function tests (n = 1) 
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o Aortic valve disease (n = 1) 
o Chronic kidney disease stage 3B (n = 1) 
o Participant’s decision to withdraw (n = 1) 
o Surplus to requirement (n = 1) 
 
72 participants were randomised. 36 participants were recruited to the 
allopurinol arm and 36 participants to the placebo arm of the trial. Eight 
participants withdrew from the study (five from the allopurinol group and three 
from the placebo group). The reasons for withdrawing from the trial included: 
participant’s preference (n = 4), depression (n = 2), metastatic bladder cancer 
(n = 1) and death (n =1).(Figure 18) None of the withdrawals were felt to be 
related to the study medication. One participant who was randomised to the 
placebo group was excluded from analysis because he was unable to undergo 
baseline CMRI because of claustrophobia. Another participant who was 
randomised to the allopurinol group, had undergone baseline CMRI but 






























































Figure 21 - CONSORT diagram 
Participants invited  
(n = 1914) 
422 positive 
responses 
1492 not interviewed 
231 unsuitable or not 
needed 
191 screened 
119 not eligible 
72 randomised 
36 assigned to 
allopurinol 
36 assigned to 
placebo 
Completed trial  
(n = 31) 
Completed trial  
(n = 32) 
Study dropout: 
- 2 depression 
- 3 patient’s 
preference  
Study dropout: 
- 1 metastatic 
bladder cancer 
- 1 death 
- 1 patient’s 
preference  
- 1 patient 
withdrawn 




3.3 Baseline Characteristics 
The baseline characteristics of the participants are outlined in Table 3. The 
study participants had a mean age of 71 years, estimated MPAP 30 mm Hg, 
mean FEV1 60% predicted, resting SaO2 96% and were predominantly male 
(62%). There were no significant differences between the groups for the 
baseline characteristics. There was no significant difference in baseline uric 
acid level, RVM/RVMI measured using CMRI, NT-ProBNP level and hs-Trop I 
level. 66 (93%) participants had COPD and 5 (7%) had IPF. 5 patients were 












 Allopurinol  
(n = 36) 
Placebo  
(n = 35) 
p 
Age (years) 70 (5) 71 (6) 0.45 
Male sex (%) 22 (61) 22 (63)  
Height (m) 1.65 (0.11) 1.68 (0.09) 0.29 
Weight (kg) 80.2 (16.6) 82.7 (17.0) 0.54 
BMI (kg/m2) 29 (5) 29 (5) 0.98 
Heart rate (bpm) 79 (14) 78 (13) 0.99 
Systolic BP (mm Hg) 138 (16) 140 (19) 0.67 
Diastolic BP (mm Hg) 76 (9) 75 (14) 0.93 
mMRC dyspnoea scale 2.8 (1.3) 2.7 (1.2) 0.14 
WHO Functional class 2.3 (0.8) 2.4 (0.7) 0.48 
Smoking status 









Pack-year history 46.9 (27.4) 50.3 (28.6) 0.61 
Long-term oxygen 3 (8) 2 (6)  
SaO2 (%) 96 (3) 96 (3) 0.67 
PAT (ms) 94.9 (9.6) 97.1 (12.1) 0.38 
 
Table 5 - Baseline characteristics 
Data are mean (SD), n (%) or median (IQR), unless otherwise indicated. 
Independent samples t-test for normally-distributed continuous variables and 
Mann-Whitney U test for non-parametric data. 
Abbreviations: BMI = body mass index; mMRC = modified medical research 





3.3.1 Past medical history and concomittant medications 
Past medical history / 
concomitant medications 
Allopurinol  
(n = 36) 
Placebo  
(n = 35) 
COPD 34 (94%) 32 (92%) 
ILD 2 (6%) 3 (8%) 
Ischaemic heart disease  17 (47%) 5 (14%) 
Hypertension 20 (56%) 20 (57%) 
Hypercholesterolaemia 22 (61%) 21 (60%) 
Cerebrovascular disease 7 (19%) 4 (11%) 
Type 2 diabetes mellitus 8 (22%) 6 (17%) 
Peripheral vascular disease  5 (14%) 3 (9%) 
LABA 29 (81%) 27 (77%) 
LAMA 26 (72%) 27 (77%) 
ICS 19 (53%) 18 (56%) 
Beta-blocker 6 (17%) 6 (17%) 
ACE inhibitor 10 (28%) 11 (31%) 
ARB 4 (11%) 3 (9%) 
Statin 23 (64%) 21 (60%) 
Diuretic 9 (25%) 9 (26%) 
 
Table 6 - Past medical history and concomitant medications 
 
Data are n (%) unless otherwise indicated.  
Abbreviations: COPD = chronic obstructive pulmonary disease; ILD = 
interstitial lung disease; LABA = long-acting beta-agonist; LAMA = long-acting 
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muscarinic antagonist; ICS = inhaled corticosteroid; ACE = angiotensin-

















3.3.2 Baseline spirometry 
COPD 
Allopurinol 
(n = 34) 
Placebo 
(n = 32) 
p 
FEV1 (L) 1.45 (0.65) 1.46 (0.66) 0.95 
FEV1 (% predicted) 60 (21) 58 (20) 0.64 
FVC (L) 2.78 (0.99) 2.94 (0.94) 0.52 
FVC (% predicted) 90 (18) 92 (21) 0.62 
FEV1/FVC (%) 52 (14) 49 (13) 0.41 
FEF25-75 0.62 (0.33) 0.60 (0.37) 0.83 
FEF25-75 (% predicted) 22 (11) 21 (11) 0.64 
 
GOLD 1 9 (26) 3 (9)  
GOLD 2 16 (47) 16 (50)  
GOLD 3 6 (18) 12 (38)  
GOLD 4 3 (9) 1 (3)  
 
Table 7- Baseline spirometry and GOLD stage for patients with COPD 
Data are mean (SD), median (IQR) or n (%), unless otherwise indicated. 
Independent samples t-test for normally-distributed continuous variables and 
Mann-Whitney U test for non-parametric data. 
Abbreviations: FEV1 = forced expiratory volume in 1 sec; FVC = forced vital 










(n = 2) 
Placebo 
(n = 3) 
p 
FEV1 (L) 2.51 (0.27) 1.94 (0.71) 0.37 
FEV1 (% predicted) 94 (6) 70 (24) 0.29 
FVC (L) 3.15 (0.42) 2.71 (0.81) 0.55 
FVC (% predicted) 91 (6.4) 81 (32) 0.71 
FEV1/FVC (%) 80 (2) 71 (9) 0.30 
FEF25-75 2.12 (0.36) 1.35 (0.83) 0.32 
FEF25-75 (% predicted) 71 (11) 44 (29) 0.33 
 
Table 8 - Baseline spirometry for patients with ILD 
Data are mean (SD) or median (IQR), unless otherwise indicated. Independent 
samples t-test for normally-distributed continuous variables and Mann-
Whitney U test for non-parametric data. 
Abbreviations: FEV1 = forced expiratory volume in 1 sec; FVC = forced vital 




















3.3.3 Baseline blood results  
 Allopurinol 
(n = 36) 
Placebo 
(n = 35) 
p 
Haemoglobin (g/dL) 141 142 0.81 
Haematocrit (l/L) 0.43 0.43 0.93 
Glucose (mmol/L) 6.3 (2.1) 5.7 (1.8) 0.20 
HDL-C (mmol/L) 1.3 (0.5) 1.5 (0.5) 0.16 
GFR (ml/min) 96.1 (24.9) 91.8 (27.7) 0.49 
Eosinophil (x 109/L) 0.22 (0.15) 0.26 (0.14) 0.25 
Neutrophil (x 109/L) 4.95 (1.36) 5.59 (1.46) 0.06 
Lymphocyte  
(x 109/L) 
1.90 (0.68) 2.16 (0.64) 0.10 
Uric acid (mmol/L) 350.1 (81.3) 342.9 (90.9) 0.73 
NT-proBNP (pg/ml) 918 (1491) 949 (1627) 0.93 
Hs-Trop I (pg/ml) 3.2 (3.3) 3.6 (4.3) 0.69 
 
Table 9 - Baseline blood results 
Data are mean (SD), n (%) or median (IQR), unless otherwise indicated. 
Peason’s chi-square was used for discrete variables, independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 
Abbreviations: HDL-C = high density lipoprotein cholesterol; GFR = glomerular 
filtration rate; NT-proBNP = N-terminal prohormone brain natriuretic peptide; 




3.3.4 Baseline CMRI measurements 
 Allopurinol 
(n = 36) 
Placebo 
(n = 35) 
p 
RVM (g) 
Normal: 28 - 49 
40.27 ± 1.62 41.19 ± 2.06 0.73 
RVMI (g/m2) 
Normal: 16 - 25 
21.02 ± 0.68 20.88 ± 0.83 0.90 
RVESV (ml) 
Normal: 39 – 98 
49.7 ± 2.9 55.8 ± 3.6 0.19 
RVEDV (ml) 
Normal: 108 - 217 
118.6 ± 5.2 129.1 ± 5.8 0.17 
RVSV (ml) 
Normal: 66 - 125 
68.8 ± 3.3 73.4 ± 3.8 0.35 
RVEF (%) 
Normal: 56 - 67 
57.0 ± 2.0 56.5 ± 1.7 0.85 
 
LVM (g) 
Normal: 77 – 155 
106.8 ± 4.8 105.9 ± 4.9 0.89 
LVMI (g/m2) 
Normal: 51 - 76 
55.5 ± 1.8 53.7 ± 2.0 0.52 
LVSV (ml) 
Normal: 72 – 126 
70.9 ± 3.4 76.3 ± 3.3 0.25 
LVEF (%) 
Normal: 62 - 72 
52.9 ± 1.9 56.8 ± 1.5 0.10 
 
Table 10 - Baseline cardiac MRI measurements 
Data are mean ± SD, unless otherwise indicated. Independent samples t-test 
for normally-distributed continuous variables and Mann-Whitney U test for non-
parametric data. 
Abbreviations: RVM = right ventricular mass; RVMI = right ventricular mass 
index; RVESV = right ventricular end-systolic volume; RVEDV = right 
ventricular end-diastolic volume; RVSV = right ventricular stroke volume; 
RVEF = right ventricular ejection fraction; LVM = left ventricular mass, LVMI = 
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left ventricular mass index; LVSV = left ventricular stroke volume; LVEF = left 
ventricular ejection fraction. 
















3.4 Effect of Allopurinol on RVM and RVMI 
71 patients underwent CMRI (allopurinol, n = 36; placebo, n = 35). At baseline, 
the right ventricular mass (RVM) and the right ventricular mass index (RVMI) 
were similar between the two groups. After 12 months of allopurinol therapy, 
in the intention-to-treat analysis, there was no significant difference in the 
change in RVM (allopurinol group 1.85 ± 1.56 g vs. placebo group 0.97 ± 1.20 
g; p = 0.66) and in the change in RVMI (allopurinol group 0.70 ± 0.75 g/m2 vs. 
placebo group 0.50 ± 0.60 g/m2; p = 0.83) between the two groups (Table 11). 
Analysis was also done on completed cases and there was no significant 
difference in change in RVM or in RVMI. Bonferroni correction was used to 
make adjustment for multiple comparisons. 
 Allopurinol 
(n = 36) 
Placebo 
(n = 35) 
p 
Baseline RVM (g) 40.27 ± 1.62 41.19 ± 2.06 0.73 
Final RVM (g) 42.13 ± 1.42 42.16 ± 1.99 0.99 
Change in RVM (g) 1.85 ± 1.56 0.97 ± 1.20 0.66 
 
Baseline RVMI (g/m2) 21.02 ± 0.68 20.88 ± 0.83 0.90 
Final RVMI (g/m2) 21.73 ± 0.57 21.39 ± 0.82 0.73 
Change in RVMI (g/m2) 0.70 ± 0.75 0.50 ± 0.60 0.83 
 
Table 11 - Effect of allopurinol on RVM and RVMI (intention-to-treat analysis) 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-




Abbreviations: RVM = right ventricular mass; RVMI = right ventricular mass 
index 
 
Figure 22 - Change in RVM 
 
 





(n = 30) 
Placebo 
(n = 32) 
p 
Baseline RVM (g) 41.4 ± 10.2 39.7 ± 13.2 0.47 
Final RVM (g) 39.1 ± 13.2 41.4 ± 11.9 0.99 
Change in RVM (g) -1.7 ± 6.8 0.0 ± 4.9 0.30 
 
Baseline RVMI (g/m2) 22.2 ± 4.7 20.6 ± 6.4 0.18 
Final RVMI (g/m2) 21.6 ± 3.8 20.8 ± 5.4 0.39 
Change in RVMI (g/m2) -0.8 ± 3.8 0.2 ± 2.2 0.25 
 
Table 12 - Effect of allopurinol on RVM and RVMI (complete-cases analysis) 
Data are presented as Median ± Interquartile range. Mann-Whitney U test for 
non-parametric data. 










3.5 Effect of Allopurinol on parameters measured on CMRI 
For the other parameters measured on cardiac MRI for both right and left 
ventricles, there were no significant changes in end-systolic volume (ESV), 
end-diastolic volume (EDV), ejection fraction (EF), stroke volume (SV) and 















3.5.1 Effect of Allopurinol on Right Ventricular volumes 
 Allopurinol 
(n = 36) 
Placebo 
(n = 35) 
p 
Baseline RVESV (ml) 49.7 ± 2.9 55.8 ± 3.6 0.19 
Final RVESV (ml) 54.5 ± 2.7 59.5 ± 4.9 0.37 
Change in RVESV (ml) 4.8 ± 2.5 3.8 ± 2.8 0.79 
 
Baseline RVESVI (ml/m2) 26.1 ± 1.6 28.3 ± 1.7 0.33 
Final RVESVI (ml/m2) 28.0 ± 1.2 30.1 ± 2.3 0.43 
Change in RVESVI (ml/m2) 1.9 ± 1.3 1.7 ± 1.4 0.92 
 
Baseline RVEDV (ml) 118.6 ± 5.2 129.1 ± 5.8 0.17 
Final RVEDV (ml) 127.4 ± 3.6 134.7 ± 6.3 0.31 
Change in RVEDV (ml) 8.8 ± 4.2 5.6 ± 4.2 0.59 
 
Baseline RVEDVI (ml/m2) 62.2 ± 2.5 65.5 ± 2.3 0.34 
Final RVEDVI (ml/m2) 66.3 ± 1.7 68.6 ± 2.5 0.45 
Change in RVEDVI (ml/m2) 4.0 ± 2.2 3.1 ± 2.2 0.75 
Table 13 - Effect of allopurinol on RVESV, RVESVI, RVEDV and RVEDVI 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-




Abbreviations: RVESV = right ventricular end-systolic volume; RVESVI = right 
ventricular end-systolic volume index; RVEDV = right ventricular end-diastolic 
















3.5.2 Effect of Allopurinol on Right Ventricular Stroke Volume & 
Ejection Fraction 
 Allopurinol 
(n = 36) 
Placebo 
(n = 35) 
p 
Baseline RVSV (ml) 68.8 ± 3.3 73.4 ± 3.8 0.35 
Final RVSV (ml) 71.8 ± 2.5 75.0 ± 3.5 0.46 
Change in RVSV (ml) 3.0 ± 3.1 1.6 ± 2.7 0.73 
 
Baseline RVSVI (ml/m2) 36.1 ± 1.7 37.2 ± 1.5 0.62 
Final RVSVI (ml/m2) 37.5 ± 1.3 38.3 ± 1.5 0.69 
Change in RVSVI (ml/m2) 1.4 ± 1.7 1.1 ± 1.3 0.88 
 
Baseline RVEF (%) 57.0 ± 2.0 56.5 ± 1.7 0.85 
Final RVEF (%) 58.3 ± 1.8 58.2 ± 2.1 0.95 
Change in RVEF (%) 1.3 ± 2.4 1.7 ± 1.7 0.91 
 
Table 14 - Effect of allopurinol on RVSV, RVSVI and RVEF 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 
Abbreviations: RVSV = right ventricular stroke volume; RVSVI = right 




3.5.3 Effect of Allopurinol on Left Ventricular Mass 
 Allopurinol 
(n = 36) 
Placebo 
(n = 35) 
p 
Baseline LVM (g) 106.8 ± 4.8 105.9 ± 4.9 0.89 
Final LVM (g) 107.6 ± 3.8 103.9 ± 4.5 0.53 
Change in LVM (g) 0.8 ± 3.2 -1.9 ± 2.8 0.52 
 
Baseline LVMI (g/m2) 55.5 ± 1.8 53.7 ± 2.0 0.52 
Final LVMI (g/m2) 55.6 ± 1.4 52.6 ± 1.9 0.21 
Change in LVMI (g/m2) 0.1 ± 1.5 -1.1 ± 1.2 0.53 
 
Table 15 - Effect of allopurinol on LVM and LVMI 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 








3.5.4 Effect of Allopurinol on Left Ventricular volumes 
 Allopurinol 
(n = 36) 
Placebo 
(n = 35) 
p 
Baseline LVESV (ml) 60.3 ± 3.3 56.2 ± 3.0 0.37 
Final LVESV (ml) 61.6 ± 3.1 59.2 ± 3.4 0.61 
Change in LVESV (ml) 1.3 ± 2.4 2.9 ± 2.6 0.63 
 
Baseline LVESVI (ml/m2) 31.4 ± 1.5 28.9 ± 1.5 0.24 
Final LVESVI (ml/m2) 31.7 ± 1.4 30.5 ± 1.7 0.57 
Change in LVESVI (ml/m2) 0.3 ± 1.2 1.6 ± 1.3 0.47 
 
Baseline LVEDV (ml) 131.2 ± 5. 132.3 ± 5.5 0.88 
Final LVEDV (ml) 138.4 ± 4.2 136.2 ± 5.5 0.74 
Change in LVEDV (ml) 7.2 ± 4.4 3.8 ± 4.1 0.57 
 
Baseline LVEDVI (ml/m2) 68.5 ± 2.4 67.7 ± 2.5 0.81 
Final LVEDVI (ml/m2) 71.9 ± 2.0 69.6 ± 2.4 0.47 
Change in LVEDVI (ml/m2) 3.4 ± 2.1 1.9 ± 2.1 0.63 
 
Table 16 - Effect of allopurinol on LVESV, LVESVI, LVEDV and LVEDVI 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-




Abbreviations: LVESV = left ventricular end-systolic volume; LVESVI = left 
ventricular end-systolic volume index; LVEDV = left ventricular end-diastolic 


























3.5.5 Effect of Allopurinol on Left Ventricular Stroke Volume & 
Ejection Fraction 
 Allopurinol 
(n = 36) 
Placebo 
(n = 35) 
p 
Baseline LVSV (ml) 70.9 ± 3.4 76.3 ± 3.3 0.25 
Final LVSV (ml) 76.7 ± 2.6 76.7 ± 3.4 0.99 
Change in LVSV (ml) 5.8 ± 3.3 0.4 ± 2.6 0.20 
 
Baseline LVSVI (ml/m2) 37.1 ± 1.6 38.9 ± 1.4 0.40 
Final LVSVI (ml/m2) 40.0 ± 1.4 39.3 ± 1.4 0.72 
Change in LVSVI (ml/m2) 2.9 ± 1.7 0.3 ± 1.4 0.25 
 
Baseline LVEF (%) 52.9 ± 1.9 56.8 ± 1.5 0.10 
Final LVEF (%) 55.9 ± 1.6 56.8 ± 1.3 0.66 
Change in LVEF (%) 3.0 ± 2.0 0.0 ± 1.3 0.20 
 
Table 17 - Effect of allopurinol on LVSV, LVSVI and LVEF 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 
Abbreviations: LVSV = left ventricular stroke volume; LVSVI = left ventricular 





3.5.6 Effect of Allopurinol on pulmonary haemodynamics 
When analysing only complete cases and those who could have pulmonary 
haemodynamics measured at baseline visit, there were no significant 
difference in the change of pulmonary haemodynamic measurements between 
allopurinol group and placebo group. 
Although there was better improvement in pulmonary acceleration time (PAT) 
in the allopurinol group, the change in PAT was not statistically significant 
within group (9.9, CI -21.0 to 1.2, p = 0.08). 
 Allopurinol 
(n = 36) 
Placebo 
(n = 35) 
p 
Baseline Pulm_PWV (ms-1) 3.69 ± 0.34 3.16 ± 0.28 0.24 
Final Pulm_PWV (ms-1) 3.48 ± 0.34 3.80 ± 0.37 0.53 
Change in Pulm_PWV (ms-1) -0.20 ± 0.45 0.64 ± 0.40 0.17 
 
Baseline PAT (ms) 107.7 ± 3.1 104.8 ± 3.4 0.52 
Final PAT (ms) 117.6 ± 3.8 106.7 ± 3.4 0.053 
Change in PAT (ms) 9.9 ± 5.4 2.0 ± 5.5 0.31 
 
Table 18 - Effect of allopurinol on pulmonary artery pulse wave velocity & 
PAT 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables. 
Abbreviations: Pulm_PWV = pulmonary artery pulse wave velocity; PAT = 
pulmonary acceleration time. 
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3.6 Effect of Allopurinol on St George Respiratory Questionnaire 
 Allopurinol 
(n = 36) 
Placebo 
(n = 35) 
p 
Baseline Total Score 47.2 ± 3.4 48.9 ± 2.9 0.71 
Final Total Score 46.3 ± 3.3 47.6 ± 2.7 0.77 
Change in Total Score -0.9 ± 1.7 -1.3 ± 2.0 0.88 
 
Baseline Symptom Score 47.1 ± 3.9 51.1 ± 3.9 0.47 
Final Symptom Score 44.3 ± 4.3 52.7 ± 3.9 0.15 
Change in Symptom Score -2.8 ± 3.0 1.6 ± 3.7 0.35 
 
Baseline Activity Score 65.5 ± 4.0 67.6 ± 3.6 0.69 
Final Activity Score 67.4 ± 4.1 66.3 ± 3.3 0.84 
Change in Activity Score 1.9 ± 2.3 -1.3 ± 2.4 0.29 
 
Baseline Impact Score 36.9 ± 3.6 37.5 ± 3.0 0.89 
Final Impact Score 35.2 ± 3.2 35.1 ± 2.7 0.99 
Change in Impact Score -1.7 ± 2.3 -2.4 ± 2.4 0.84 
 
Table 19 - Mean change in SGRQ scores 
 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-





3.7 Effect of Allopurinol on Short Form 36 
 Allopurinol 
(n = 36) 
Placebo 
(n = 35) 
p 
Physical functioning 
Baseline  39.4 ± 4.7 33.7 ± 4.4 0.37 
Final 38.4 ± 4.6 36.6 ± 3.9 0.77 
Change -1.1 ± 3.1 2.9 ± 2.4 0.31 
Physical role limitations 
Baseline  35.4 ± 6.3 22.1 ± 5.4 0.11 
Final 37.1 ± 6.3 30.3 ± 5.9 0.44 
Change 1.7 ± 5.7 8.2 ± 6.4 0.45 
Emotional role limitations 
Baseline  61.1 ± 7.5 46.7 ± 6.9 0.15 
Final 55.3 ± 7.2 48.1 ± 7.6 0.49 
Change -5.8 ± 6.5 1.5 ± 8.5 0.50 
Energy or fatigue 
Baseline  47.1 ± 3.4 45.1 ± 3.0 0.67 
Final 46.3 ± 3.4 49.7 ± 3.2 0.47 
Change -0.8 ± 2.6 4.5 ± 3.8 0.25 
Emotional well-being 
Baseline  70.1 ± 3.2 73.4 ± 2.7 0.44 
Final 74.8 ± 2.3 73.7 ± 3.0 0.77 




Baseline  71.2 ± 4.1 71.4 ± 4.4 0.97 
Final 68.8 ± 4.5 69.8 ± 4.3 0.87 
Change -2.4 ± 3.6 -1.6 ± 4.0 0.88 
Pain 
Baseline  64.8 ± 4.9 62.6 ± 5.0 0.75 
Final 60.7 ± 4.8 63.7 ± 4.7 0.66 
Change -4.1 ± 3.5 1.1 ± 4.7 0.37 
General health 
Baseline  43.1 ± 3.4 41.9 ± 3.5 0.81 
Final 43.2 ± 3.1 41.8 ± 2.6 0.74 
Change 0.1 ± 2.7 -0.0 ± 3.3 0.97 
Health change 
Baseline  47.9 ± 3.5 39.3 ± 4.0 0.10 
Final 53.5 ± 2.5 46.2 ± 2.9 0.06 
Change 5.6 ± 4.0 7.0 ± 5.3 0.83 
 
Table 20 - Mean change in SF-36 scores 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-







3.8 Effect of Allopurinol on King’s Brief Interstitial Lung Disease  
questionnaire 
Five patients (3 in placebo and 2 in allopurinol) with ILD completed the King’s 
Brief Interstitial Lung Disease (K-BILD) questionnaire at baseline but only three 
completed the study (2 in placebo and 1 in allopurinol). Completed cases 
analysis was done. At baseline, the patient in the allopurinol group had higher 
scores in all the four different domains (psychological score, breathless score, 
breathlessness and activities score, chest symptom score, and total score) 
compared to the two patients in the placebo group. An improvement in all four 
domains was observed in the two patients in the placebo group compared to 
the one patient in allopurinol group whose scores all decreased after 12 











3.9 Effect of Allopurinol on BDI-TDI 
When analysing completed cases who had both BDI and TDI measured (n = 
54), there was a significant difference in the TDI score (p = 0.02). 9 of the total 
completed cases were not analysed as these participants indicated that it was 
not breathlessness which was the underlying cause for their limitation in 
exercise capacity. 
 Allopurinol 
(n = 28) 
Placebo 
(n = 26) 
p 
BDI 5.5 ± 1.7 5.4 ± 2.0 0.88 
TDI -0.7 ± 0.9 -0.1 ± 0.9 0.02 
 
Table 21 - Effect of allopurinol on BDI-TDI score 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 









3.10 Effect of Allopurinol on spirometry 
The baseline spirometric measurements were similar in both allopurinol and 
placebo groups. The spirometric measurements include FEV1, FVC and FEF25-
75. Allopurinol did not produce any significant change in the spirometric 
measurements after 12 months of treatment. There were also no significant 
differences in the change in spirometric measurements between the two 













3.11 Effect of Allopurinol on 6-minute walk test 
The total walking distance in metres, the pre-test O2, the post-test O2, the pre-
test HR, the post-test HR, the pre-test Borg Dyspnoea score, the post-test 
Borg Dyspnoea score, the pre-test Borg Fatigue score and the post-test Borg 
Fatigue score were measured for each 6MWT. Missing values were calculated 
using multiple imputations. The mean change in the parameters were then 
calculated, comparing those on allopurinol with those on placebo. 
 Allopurinol 
(n = 36) 
Placebo 
(n = 35) 
p 
Baseline distance 355.3 ± 17.4 375.6 ± 16.5 0.40 
Final distance 364.1 ± 15.1 365.6 ± 16.7 0.95 
Change in distance 8.8 ± 10.0 -10.0 ± 12.5 0.24 
 
Baseline pre-test O2 95.8 ± 0.5 95.5 ± 0.5 0.67 
Final pre-test O2 95.4 ± 0.4 94.8 ± 0.7 0.39 
Change in pre-test O2 -0.4 ± 0.3 -0.8 ± 0.4 0.51 
 
Baseline post-test O2 91.9 ± 1.3 90.8 ± 1.1 0.52 
Final post-test O2 90.6 ± 0.8 90.2 ± 1.1 0.79 
Change in post-test O2 -1.3 ± 0.9 -0.5 ± 0.8 0.52 
 
Baseline pre-test HR 80.0 ± 2.3 82.3 ± 3.1 0.54 
Final pre-test HR 78.8 ± 2.3 79.2 ± 2.5 0.90 
Change in pre-test HR -1.2 ± 2.3 
 




Baseline post-test HR 94.1 ± 2.8 102.9 ± 4.4 0.88 
Final post-test HR 97.9 ± 2.6 100.2 ± 3.3 0.57 
Change in post-test HR 3.8 ± 2.1 -2.6 ± 3.6 0.12 
 
Baseline pre-test Dyspnoea 
Score 
0.8 ± 0.2 0.8 ± 0.2 0.99 
Final pre-test Dyspnoea 
Score 
1.1 ± 0.2 1.0 ± 0.2 0.86 
Change in pre-test 
Dyspnoea Score 




3.4 ± 0.4 3.0 ± 0.3 0.37 
Final post-test Dyspnoea 
Score 
3.4 ± 0.4 3.8 ± 0.5 0.48 
Change in post-test 
Dyspnoea Score 
0.0 ± 0.4 
 
0.9 ± 0.5 0.19 
 
Table 22 - Mean change in 6MWT measurements 
 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 







3.12 Effect of Allopurinol on blood markers 
The blood markers that were measured at baseline and at final visits were NT-
proBNP, hs-Trop I and urate levels. Allopurinol did not significantly reduced 
NT-proBNP and hs-Trop I level compared with placebo. Allopurinol 
significantly reduced serum uric acid (allopurinol group -205.9 ± 14.9 vs. 
placebo group -4.6 ± 8.5; p < 0.001). The serum uric acid level was reduced 
by 59% with allopurinol treatment.  
 
 Allopurinol 
(n = 36) 
Placebo 















Change in NT-proBNP 
(pg/ml) 
-87.6 ± 127.2 289.4 ± 213.3 0.13 
 
Baseline hs-Trop I (pg/ml) 
3.22 ± 0.55 3.59 ± 0.73 0.69 
Final hs-Trop I (pg/ml) 
3.03 ± 0.41 3.77 ± 0.79 0.40 
Change in hs-Trop I 
(pg/ml) 
-0.20 ± 0.48 0.18 ± 0.37 0.53 
 
Baseline Urate (μmol/l) 
350.06 ± 13.54 342.94 ± 15.37 0.73 
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Final Urate (μmol/l) 
144.12 ± 9.12 338.34 ± 15.59 < 0.001 
Change in Urate (μmol/l) -205.9 ± 14.9 
 
-4.6 ± 8.5 < 0.001 
 
Table 23 - Change in blood markers 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 
Abbreviations: NT-proBNP = N-terminal prohormone of brain natriuretic 












3.13 Subgroup analysis 
To look whether any subgroup might have benefitted from allopurinol, the 
participants were stratified by high/low baseline RVM, high/low baseline RVMI, 
high/low baseline serum urate level, high/low baseline pulmonary acceleration 
time (measured by doppler echocardiography), high/low baseline NT-proBNP 
level and high/low baseline six-minute walk distance using the median values 
of the corresponding parameter, and by COPD GOLD stage. The study was 
not powered to evaluate subgroups, but these post-hoc subgroup analyses 












3.13.1 Subgroup analysis stratified by median of RVM 
The median for baseline right ventricular mass (RVM) is 39.56g. 
 
Allopurinol 
(n = 18) 
Placebo 
(n = 16) 
p 
Baseline RVM (g) 47.73 ± 1.35 50.69 ± 2.55 NS 
Final RVM (g) 46.56 ± 2.01 49.40 ± 3.04 NS 
Change in RVM (g) -1.17 ± 1.67 -1.29 ± 1.49 0.96 
 
Baseline RVMI (g/m2) 23.38 ± 0.70 24.47 ± 1.09 NS 
Final RVMI (g/m2) 22.94 ± 0.82 24.04 ± 1.40 NS 
Change in RVMI (g/m2) -0.44 ± 0.83 -0.44 ± 0.71 0.997 
 
Table 24 - Effect of allopurinol on RVM and RVMI for participants with RVM > 
39.56 g 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 









(n = 13) 
Placebo 
(n = 15) 
p 
Baseline RVM (g) 
35.00 ± 1.44 33.19 ± 1.29 
NS 
Final RVM (g) 
35.45 ± 1.19 35.01 ± 1.85 
NS 
Change in RVM (g) 
-0.85 ± 1.25 1.82 ± 1.15 
0.13 
 
Baseline RVMI (g/m2) 
19.63 ± 0.73 17.88 ± 0.44 NS 
Final RVMI (g/m2) 
19.84 ± 0.65 18.93 ± 0.63 NS 
Change in RVMI (g/m2) 
-0.38 ± 0.65 1.05 ± 0.61 0.12 
 
Table 25 - The effect of allopurinol on RVM and RVMI for participants with 
RVM < 39.56 g 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 







3.13.2 Subgroup analysis stratified by median of RVMI 
The median for baseline right ventricular mass index (RVMI) is 20.72 g/m2. 
 
Allopurinol 
(n = 19) 
Placebo 
(n = 14) 
p 
Baseline RVM (g) 
46.07 ± 1.63 51.29 ± 2.89 NS 
Final RVM (g) 
42.77 ± 2.24 50.05 ± 3.43 NS 
Change in RVM (g) 
-3.30 ± 1.29 -1.24 ± 1.70 0.33 
 
Baseline RVMI (g/m2) 
23.88 ± 0.50 25.29 ± 1.06 NS 
Final RVMI (g/m2) 
22.33 ± 0.85 25.00 ± 1.43 NS 
Change in RVMI (g/m2) 
-1.55 ± 0.65 -0.30 ± 0.82 0.24 
 
Table 26- Effect of allopurinol on RVM and RVMI for participants with RVMI > 
20.72 g/m2 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 







(n = 11) 
Placebo 
(n = 18) 
p 
Baseline RVM (g) 
38.12 ± 1.37 34.94 ± 1.48 NS 
Final RVM (g) 
40.98 ± 2.29 35.90 ± 1.75 NS 
Change in RVM (g) 
2.86 ± 1.42 0.96 ± 1.09 0.30 
 
Baseline RVMI (g/m2) 
19.08 ± 0.24 18.11 ± 0.41 NS 
Final RVMI (g/m2) 
20.62 ± 0.77 18.62 ± 0.54 NS 
Change in RVMI (g/m2) 
1.54 ± 0.70 0.51 ± 0.58 0.24 
 
Table 27 - Effect of allopurinol on RVM and RVMI for participants with RVMI 
< 20.72 g/m2 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 







3.13.3 Subgroup analysis stratified by median of urate level 
The median for serum urate level is 334 μmol/l. 
 
Allopurinol 
(n = 18) 
Placebo 
(n = 13) 
p 
Baseline RVM (g) 
44.03 ± 1.97 47.86 ± 3.64 NS 
Final RVM (g) 
44.34 ± 1.95 48.21 ± 3.96 NS 
Change in RVM (g) 
0.31 ± 1.44 0.36 ± 2.12 0.99 
 
Baseline RVMI (g/m2) 
21.71 ± 0.72 22.91 ± 1.66 NS 
Final RVMI (g/m2) 
22.10 0.72 23.34 ± 1.87 NS 
Change in RVMI (g/m2) 
0.39 ± 0.71 0.43 ± 0.97 0.97 
 
Table 28 - Effect of allopurinol on RVM and RVMI for participants with urate > 
334 μmol/l 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 





There were significant differences in the change in RVM and RVMI between 
allopurinol and placebo groups in the participants with low baseline urate level 
(< 334 μmol/l). However, these differences are statistically significant because 
there was already significant difference in baseline RVM and RVMI between 
both groups.(Table 29) 
 
Allopurinol 
(n = 12) 
Placebo 
(n = 18) 
p 
Baseline RVM (g) 
41.84 ± 1.59 38.15 ± 2.22 0.030 
Final RVM (g) 
38.77 ± 2.65 38.27 ± 2.10 NS 
Change in RVM (g) 
-3.07 ± 1.60 0.12 ± 0.77 0.009 
 
Baseline RVMI (g/m2) 
22.74 ± 0.80 20.11 ± 0.75 0.081 
Final RVMI (g/m2) 
21.10 ± 1.12 20.29 ± 0.68 NS 
Change in RVMI (g/m2) 
-1.64 ± 0.79 0.18 ± 0.47 0.010 
 
Table 29 - Effect of allopurinol on RVM and RVMI for participants with urate < 
334 μmol/l 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 




3.13.4 Subgroup analysis stratified by median of pulmonary 
acceleration time 
The median for pulmonary acceleration time (PAT) is 97 ms. 
 
Allopurinol 
(n = 15) 
Placebo 
(n = 16) 
p 
Baseline RVM (g) 
42.49 ± 1.84 36.75 ± 1.71 0.030 
Final RVM (g) 
43.03 ± 2.39 37.21 ± 1.82 NS 
Change in RVM (g) 
0.54 ± 1.67 0.45 ± 1.15 0.97 
 
Baseline RVMI (g/m2) 
21.47 ± 0.68 19.65 ± 0.74 NS 
Final RVMI (g/m2) 
21.72 ± 0.86 20.17 ± 0.70 NS 
Change in RVMI (g/m2) 
0.25 ± 0.82 0.52 ± 0.59 0.79 
 
Table 30 - Effect of allopurinol on RVM and RVMI for participants with PAT > 
97 ms 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 







(n = 15) 
Placebo 
(n = 15) 
p 
Baseline RVM (g) 
43.82 ± 1.99 48.06 ± 3.51 NS 
Final RVM (g) 
41.20 ± 2.27 48.02 ± 3.68 NS 
Change in RVM (g) 
-2.62 ± 1.37 -0.04 ± 1.64 0.24 
 
Baseline RVMI (g/m2) 
22.77 ± 0.82 23.02 ± 1.46 NS 
Final RVMI (g/m2) 
21.69 ± 0.92 23.06 ± 1.65 NS 
Change in RVMI (g/m2) 
-1.08 ± 0.73 0.04 ± 0.79 0.31 
 
Table 31 - Effect of allopurinol on RVM and RVMI for participants with PAT > 
97 ms 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 







3.13.5 Subgroup analysis stratified by median of NT-proBNP level 
The median for NT-proBNP level is 489.53 pg/ml. 
 
Allopurinol 
(n = 13) 
Placebo 
(n = 18) 
p 
Baseline RVM (g) 
40.52 ± 1.99 44.47 ± 3.08 NS 
Final RVM (g) 
41.56 ± 2.17 43.91 ± 3.38 NS 
Change in RVM (g) 
1.04 ± 1.33 -0.56 ± 4.42 0.44 
 
Baseline RVMI (g/m2) 
20.93 ± 0.96 22.62 ± 1.22 NS 
Final RVMI (g/m2) 
21.56 ± 0.83 22.57 ± 1.43 NS 
Change in RVMI (g/m2) 
0.63 ± 0.72 -0.05 ± 0.67 0.50 
 
Baseline LVEF 
52.49 ± 3.00 56.82 ± 3.00 NS 
Final LVEF 
57.61 ± 2.34 55.20 ± 2.26 NS 
Change in LVEF 
5.12 ± 2.36 -1.62 ± 1.51 0.017 
 
Table 32 - Effect of allopurinol on RVM, RVMI and LVEF for participants with 
NT-proBNP > 489.53 pg/ml 
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Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 
Abbreviations: RVM = right ventricular mass; RVMI = right ventricular mass 




Figure 24 - Change in LVEF for participants with high NT-proBNP 
 
There were no significant differences in the change from baseline in the other 
RV and LV parameters when comparing allopurinol group with placebo group, 



































(n = 17) 
Placebo 
(n = 14) 
p 
Baseline RVM (g) 
45.17 ± 1.69 39.03 ± 2.52 0.047 
Final RVM (g) 
42.54 ± 2.40 39.74 ± 2.39 NS 
Change in RVM (g) 
-2.62 ± 1.58 0.71 ± 1.28 0.12 
 
Baseline RVMI (g/m2) 
23.03 ± 0.53 19.49 ± 0.84 0.001 
Final RVMI (g/m2) 
21.81 ± 0.90 19.91 ± 0.73 NS 
Change in RVMI (g/m2) 
-1.22 ± 0.77 0.42 ± 0.72 0.14 
 
   
Baseline LVEF 
55.46 ± 1.29 59.07 ± 2.10 NS 
Final LVEF 
54.58 ± 2.75 59.10 ± 1.65 NS 
Change in LVEF 
-0.87 ± 2.02 0.03 ± 1.56 0.73 
 
Table 33 - Effect of allopurinol on RVM, RVMI and LVEF for participants with 
NT-proBNP < 489.53 pg/ml 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 
Abbreviations: RVM = right ventricular mass; RVMI = right ventricular mass 
index, LVEF = left ventricular ejection fraction. 
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3.13.6 Subgroup analysis stratified by median of 6MWD 
The median for six-minute walk distance (6MWD) is 384.5 m. 
 Allopurinol 
(n = 13) 
Placebo 
(n = 18) 
p 
Baseline RVM (g) 
40.88 ± 2.07 43.65 ± 2.46 NS 
Final RVMI (g) 
39.86 ± 1.77 43.46 ± 2.32 NS 
Change in RVMI (g) 
-1.02 ± 1.82 -0.19 ± 1.29 0.71 
 
Baseline RVM (g/m2) 
21.03 ± 0.53 21.37 ± 1.05 NS 
Final RVMI (g/m2) 
20.75 ± 0.63 21.49 ± 1.03 NS 
Change in RVMI (g/m2) 
-0.27 ± 0.89 0.13 ± 0.60 0.70 
 
Table 34 - Effect of allopurinol on RVM and RVMI for participants with 6MWD 
> 384.5 m 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 






(n = 17) 
Placebo 
(n = 13) 
p 
Baseline RVM (g) 
44.89 ± 1.68 40.24 ± 3.87 NS 
Final RVM (g) 
43.84 ± 2.50 41.02 ± 4.28 NS 
Change in RVM (g) 
-1.06 ± 1.40 0.78 ± 1.53 0.39 
 
Baseline RVMI (g/m2) 
22.96 ± 0.81 21.16 ± 1.45 NS 
Final RVMI (g/m2) 
22.43 ± 0.96 21.67 ± 1.67 NS 
Change in RVMI (g/m2) 
-0.53 ± 0.72 0.50 ± 0.82 0.35 
 
Table 35 - Effect of allopurinol on RVM and RVMI for participants with 6MWD 
< 384.5 m 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 











3.13.7 Subgroup analysis stratified by FEV1 GOLD Stage 
 
 Allopurinol 
(n = 23) 
Placebo 
(n = 18) 
p 
Baseline RVM (g) 
42.87 ± 1.57 43.44 ± 2.71 NS 
Final RVM (g) 
43.39 ± 1.83 43.27 ± 2.42 NS 
Change in RVM (g) 
0.52 ± 1.13 -0.17 ± 1.17 0.68 
 
Baseline RVMI (g/m2) 
21.53 ± 0.57 21.48 ± 1.06 NS 
Final RVMI (g/m2) 
21.94 ± 0.68 21.58 ± 1.02 NS 
Change in RVMI (g/m2) 
0.41 ± 0.57 0.10 ± 0.58 0.71 
 
Table 36 - Effect of allopurinol on RVM and RVMI for participants with FEV1 
GOLD Stages 1 & 2 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 










(n = 7) 
Placebo 
(n = 13) 
p 
Baseline RVM (g) 
44.09 ± 2.72 40.54 ± 3.56 NS 
Final RVM (g) 
37.92 ± 3.27 41.29 ± 4.17 NS 
Change in RVM (g) 
-6.16 ± 1.97 0.75 ± 1.71 0.022 
 
Baseline RVMI (g/m2) 
24.07 ± 1.15 21.00 ± 1.42 NS 
Final RVMI (g/m2) 
20.93 ± 1.49 21.54 ± 1.67 NS 
Change in RVMI (g/m2) 
-3.13 ± 1.00 0.54 ± 0.85 0.015 
 
Table 37 - Effect of allopurinol on RVM and RVMI for participants with FEV1 
GOLD Stages 3 & 4 
Data are mean ± SEM, unless otherwise indicated. Independent samples t-
test for normally-distributed continuous variables and Mann-Whitney U test for 
non-parametric data. 






















3.14 Adverse Events (AE) 
There was a total of 179 adverse events recorded: 
• 99 AE’s in placebo group 
o 5 AE’s possible causality from IMP, all recovered 
• 80 AE’s in allopurinol group 
o 3 AE’s possible causality from IMP from same participant 
(malaise x2, lethargy). All three adverse events recovered when 
IMP dose reduced. 
 
There were 7 serious adverse events (SAE) in the allopurinol group: 
• Infective exacerbation of COPD 
• Pneumonia 
• Left leg cellulitis 
• Prostate cancer 
• Acute encephalopathy – unclear cause, probable opiate intoxication 
• Transient oesophageal obstruction 
• Community acquired pneumonia 
 
There were 15 SAE’s in the placebo group: 
• Dehydration and chest infection 
• Bladder tumour 
• Metastatic cancer 
• Drug-induced syncope 
• Non-specific abdominal pain 
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• Diverticular disease 
• Fracture left neck of femur 
• Rectal bleed due to diverticular disease 
• Urinary tract infection 
• Postural hypotension 
• Rectus sheath haematoma 
• Atrial flutter 
• Syncope 
• Death due to atherosclerosis 












3.15 Study drug compliance 
The change in serum uric acid levels reflect the study drug compliance. 
Allopurinol reduced serum uric acid level by 59% after 12 months of therapy 
whilst there was no significant change in the placebo arm. All the participants 
in the allopurinol group had a reduction in uric acid levels, suggesting that they 
were compliant in taking the study drug.  
In addition, the number of tablets returned by each participant was counted at 
each study visit. All the participants included in the study analysis had a 
compliance of more than 70%. The overall average drug compliance was 96% 












In summary, this randomised, double-blind, placebo-controlled, parallel-group 
study aimed to evaluate whether treatment with high dose allopurinol would 
regress right ventricular hypertrophy in patients with pulmonary hypertension 
associated with chronic lung disease (i.e chronic obstructive pulmonary 
disease, interstitial lung disease). In this section, the findings of the study will 
be discussed and the possible underlying mechanism for these findings. The 























4.1 Primary outcome: Right Ventricular Mass & Right Ventricular Mass 
Index 
The study was powered to detect a 5 g change in right ventricular mass (RVM). 
Despite having a similar baseline right ventricular mass in both allopurinol and 
placebo groups, there was no significant difference in the change in RVM 
between the two groups (allopurinol 1.85 g vs placebo 0.97 g) using intention-
to-treat analysis. The complete-cases analysis resulted in similar finding. The 
possible reasons for why the overall study result was negative are the lack of 
effect of allopurinol on the right ventricle and the heterogeneity of this current 
study population. These are discussed in more details subsequently. 
The mechanism underlying right ventricular hypertrophy (RVH) may be 
different from left ventricular hypertrophy (LVH). Most studies investigating 
cardiac hypertrophy120,121 mainly looked at the left ventricle. Many of the 
findings from these studies are then translated from LVH to RVH. The current 
study did the same as it was based on findings from previous studies151,173,174 
where allopurinol was found to regress LVH. In addition, Rekhraj et al.173 
demonstrated in their study that allopurinol reduced LV end systolic volume 
and LV afterload, suggesting that offloading the LV may have been the 
mechanism for the LVH regression.  Therefore, the underlying mechanism for 
right ventricular hypertrophy could involve more than oxidative stress and 
mechanical stretch due to increased afterload pressure. Allopurinol could still 
have had an effect on the right ventricle by decreasing oxidative stress which 
is directly implicated in ventricular hypertrophy. However, the effect from 
allopurinol may have been too small to be demonstrated in this study. 
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A second explanation is that the participants who were enrolled in the study 
were heterogeneous in terms of the severity of their chronic lung disease.  
Recent studies21 have demonstrated the wide range of phenotypes and 
heterogeneity of patients suffering from COPD. Hence the overall effect of 
allopurinol on right ventricular hypertrophy could have been different if we had 
considered only patients with specific phenotypes of the disease. As it was a 
proof of concept study, it was difficult to restrict to specific phenotypes as there 
was no previous studies that had already evaluated this 
As described above, the heterogenous study population may have masked a 
possible effect of allopurinol. This is supported by the finding that there was a 
statistically significant difference in the allopurinol group (-6.16 g) compared to 
the placebo group (0.75 g) when complete-case analysis was performed in a 
subgroup of patients with more severe airflow obstruction (i.e patients with 
COPD GOLD 3 and 4). This positive finding suggests that the worse the lungs 
are, the more likely allopurinol will regress right ventricular hypertrophy. A 
potential explanation for the positive finding in more severe airflow limitation is 
that these patients are more likely to be more hypoxic on exertion (despite 
having satisfactory resting oxygen saturation), causing increasing oxidative 
stress, leading to cardiac hypertrophy and increased pulmonary arterial 
pressures on exercise. However, this result should be interpreted with caution 
as the study was not powered to investigate this subgroup and the number of 
patients in this subgroup (n = 20) was relatively small. On the other hand, this 
could still be a signal that allopurinol could have a beneficial effect in patients 
with more severe airflow obstruction and future trials studying this population 
could unmask this effect. 
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Another possible explanation for the overall negative result for the primary 
outcome is that the study population consisted mostly of patients with chronic 
obstructive pulmonary disease (93%) and a few patients suffering from 
interstitial lung disease (7%). It was agreed at the time when the study was 
designed to include only patients suffering from group 3 pulmonary 
hypertension. However, it is still not completely clear whether the 
pathophysiology underlying the development of pulmonary hypertension and 
right ventricular hypertrophy is the same for all the chronic lung diseases.  
The right ventricular mass of this study population was relatively not too high 
compared to studies in patients with idiopathic pulmonary arterial 
hypertension203,205-209. This is probably because pulmonary hypertension in 
COPD and ILD patients tends to be milder in severity compared to group 1 
patients.1 There is reason to think that with bigger RVH, the effect of allopurinol 
would be more appreciable. However, this was not demonstrated in this 
current study as despite stratifying by high/low baseline RVM or RVMI, there 
was no significant difference in the change in RVM and in RVMI in the 
subgroup of participants with high baseline RVM or RVMI.  
It is difficult to compare the results of the current study with other randomised 
clinical trial (RCT) as to this date there is no other RCT which has been done 
looking at the cardiac mass, volume and function in patients with group 3 
pulmonary hypertension. The closest studies that could be compared with are 
longitudinal studies in patients with group 1 pulmonary hypertension who 
received drug therapies already licensed to treat pulmonary hypertension in 
this group. The results from these studies were mixed: the studies by 
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Michelakis et al.207, van Wolferen et al.205 and van de Veerdonk209, and the 
SERAPH study203 have reported a reduction in RV mass from baseline while 
the study by Roeleveld et al.208 and the EURO-MR study206 reported no 
change in RVM. 
To look if there was any other subgroup that might have benefitted from 
allopurinol, the participants were also stratified by high/low baseline serum 
urate level, high/low baseline pulmonary acceleration time (measured by 
doppler echocardiography), high/low baseline NT-proBNP level and high/low 
baseline six-minute walk distance, using the median values of the 
corresponding parameter. None of these subgroups made any changes to the 
results of change in RVM and in RVMI. The study was not powered to evaluate 
subgroups, but these subgroup analyses were included to help demonstrate 























4.2 Right ventricular mass as primary outcome measure 
There were several reasons to have RV as the primary outcome. Allopurinol 
was likely to exert benefits on RVM which are not due to the pulmonary 
vasculature. The pathophysiology of the right ventricle in lung disease is more 
complex than pulmonary hypertension simply increasing RV afterload and RV 
mass, as exemplified by the fact that RVH often occurs in COPD before 
pulmonary vascular abnormalities.89 This is almost certainly because oxidative 
stress in lung disease independently causes both RVH and pulmonary 
vascular abnormalities.  There is experimental evidence demonstrating a 
strong direct effect of OS promoting ventricular hypertrophy.120  Since 
allopurinol profoundly reduces OS, it is likely to reduce RV structure and 
function by a direct effect on the RV before it also reduces RVH by causing 
pulmonary vasodilatation. 
Since RVH is the initiating step in the progression to right ventricular failure in 
lung disease, its reversal is a key surrogate and allopurinol was likely to do this 
both directly (on the RV) and indirectly by acting on the pulmonary vasculature.  
This dual effect emphasies why RVH is the best surrogate by which to judge 
allopurinol rather than the pulmonary vasculature as there are likely to be RVH 
effects of allopurinol which are not due to pulmonary vascular effects (and are 
due instead to altering OS). Therefore, in the unlikely event that allopurinol 
does not alter the pulmonary vasculature, it could still benefit the RV (by 
reducing OS), which is why RVH was the primary. 
Furthermore, since RVH leads to RV dysfunction, it seems better to tackle the 
initiating event rather than trying to target a downstream event like RV 
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dysfunction which could be harder to alter.  Overall, RVM is the pivotal 
endpoint in this proof of concept study as it is the central link between OS, and 
















4.3 Secondary outcomes 
4.3.1 Other cardiac MRI measurements 
As the non-invasive cardiac MRI scan provides a comprehensive picture of the 
right ventricular structure and function206, right ventricular volumes and 
function were also measured. Right ventricular end-diastolic volume (RVEDV), 
end-systolic volume (RVESV), stroke volume (RVSV) and ejection fraction 
(RVEF) were measured at baseline and after 12-month of treatment. There 
were no significant differences in the baseline right ventricular volumes and 
function. After twelve months of treatment, there were no significant 
differences in the change in RVEDV, RVESV, RVSV, RVEF and their index 
values. 
The left ventricular volumes (LVEDV, LVESV, LVSV) and ejection fraction 
(LVEF) were also measured at baseline and at final visit. Despite similar 
baseline measurements in both groups (allopurinol and placebo), there were 
no significant differences in the change in LVEDV, LVESV, LVSV, LVEF and 
their index values between the two groups.  
Improvements in left ventricular volumes were reported in other studies with 
allopurinol. Kao et al.151 have demonstrated that allopurinol tended to cause a 
fall in LVEDV in patients with chronic kidney disease (allopurinol -9.64 ml vs 
placebo -1.65 ml, p = 0.084). Rekhraj et al.173 have reported a significant 
reduction in LVESV in allopurinol (-2.18 ml) compared to placebo (+1.3 ml) in 
patients with ischaemic heart disease. The absence of change in ventricular 
volumes in the current study could possibly be because the underlying 
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pathophysiological process of pulmonary hypertension affecting the heart is 
different compared with chronic kidney disease and ischaemic heart disease. 
Two recent studies210,211 have reported improvements in ventricular volumes 
and function in COPD population when treatment with inhaled therapy. 
However, these studies were looking at a particular phenotype of COPD 
population, namely with lung hyperinflation. There was no such emphasis in 
the current study. There was also no formal assessment lung hyperinflation in 
the study which is usually done by body plethysmography. In addition, the 
absence of change in ventricular volumes adds more evidence that allopurinol 
did not have any effect on lung volumes. 
Subgroup analyses for other CMRI measurements were done like the ones 
done for the primary outcome. The subgroup analysis when stratifying by 
high/low NT-proBNP level has shown some promising results. The patients (n 
= 31) with higher NT-proBNP level (> 489 pg/ml) had a greater improvement 
in LVEF with allopurinol +5.12% vs placebo -1.62% (mean diff 7.33, CI 1.88 to 
12.78, p = 0.02). A possible mechanism for this positive finding is that 
allopurinol could be improving cardiac energetics by improving relative and 
absolute concentrations of myocardial high-energy phosphates and ATP flux 






4.3.2 Six-minute walk distance 
There was non-significant difference in the baseline six-minute walk distance 
(6MWD) between the allopurinol group (355.3 m) and the placebo group 
(375.6 m). After 12 months of treatment, a slight increase in 6MWD was 
observed in the allopurinol group (8.8 m) compared to a decrease in the 
placebo group (-10.0 m). The difference in the change in 6MWD between the 
two groups was not statistically significant.  
The improvement in 6MWD in the allopurinol group did not reach the minimal 
clinically important difference (MCID) of 33 m which is usually quoted in studies 
for pulmonary hypertension. The worsening in 6MWD in the placebo group 
was likely due to the progression of the underlying chronic lung disease with 
associated deconditioning. Hence, these findings may suggest that allopurinol 
might have had an effect by decreasing the rate of deterioration in 6MWD. 
However, as the improvement in 6MWD in the allopurinol group was not 
statistically significant and did not reach MCID, it is difficult to be sure about 
this beneficial effect of allopurinol. Further studies with a bigger population 
looking at 6MWD as primary outcome would help to evaluate this further. 
6MWD does not solely reflect cardiac function and can be affected by factors 
such as motivation, mood, co-morbidities, patient’s age, height, weight and 
muscular training.7 Hence any improvement in 6MWD does not automatically 
imply that allopurinol improved 6MWD by improving cardiac function. 
In addition, it was noted that allopurinol did not affect the pre-test and post-test 
oxygen saturation, heart rate, Borg dyspnoea score and Borg fatigue score. 
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Other exercise tests have been used to measure exercise capacity in various 
medical conditions. These include incremental exercise tests such as cycling 
exercise test (CPET) and incremental shuttle walk test (ISWT), and endurance 
exercise tests such as cycle endurance test (CET) and endurance shuttle walk 
test (ESWT). Mainguy et al. have demonstrated in their study that the four 
exercise tests described above (CPET, ISWT, CET and ESWT) all have some 
correlation with the pulmonary pressures but using them as an alternative to 
6MWT for tracking beneficial clinical changes following therapy remained to 
be confirmed.212 A previous study from the same group showed that 6MWT 
had the best ability, compared with CET and ESWT, to capture changes in 
exercise capacity and less variation between repeated measures when 
sildenafil was added to patient’s baseline monotherapy.213  
Actigraphy is a promising novel tool that assesses 24-hour activity patterns of 
ambulatory patients (reflecting the patient’s activity during daily life at home). 
It has the potential to serve as a prognostic and outcome parameter in practice 
and in scientific trials. Ulrich et al. used wrist actigraphy in their study which 
demonstrated that patients (diagnosed with PAH or CTEPH) with a duration of 
daily activity of less than 15 hours had a significant shorter survival without 
lung transplantation compared to patients who were more active.214 The 
usefulness of actigraphy needs to be confirmed in larger cohorts. In addition, 
a direct comparison between actigraphy and 6MWT is also required to see if it 
could be used as an alternative to 6MWT in the assessment of exercise 




4.3.3 Blood markers 
NT-proBNP is a marker of disease progression in patients with pulmonary 
hypertension. The ESC/ERS guidelines1 advocate using serial measurements 
of NT-proBNP to monitor disease progression and to assess treatment effects.  
The baseline NT-proBNP levels were similar in both groups (allopurinol 916.81 
pg/ml vs placebo 949.31 pg/ml). These baseline values were above the 300 
pg/ml threshold which put the study population in the intermediate-severe risk 
category as defined by the ESC guidelines1. 
The NT-proBNP level was increased in the placebo group (+289.4 pg/ml) 
compared to a slight reduction in the allopurinol group (-87.6 pg/ml) after 12 
months. Although the difference in the change in NT-proBNP levels was not 
significant between the two groups, this may suggest that there was possibly 
a worsening of the heart function with time in the placebo group and that 
allopurinol may have some beneficial effects on the heart. It is difficult to prove 
this theory as there was no significant change in cardiac measurements done 
in this study after 12 months of treatment. High plasma levels and in particular, 
a further increase in plasma BNP have a strong independent association with 
mortality.7 Hence, if allopurinol does reduce plasma BNP levels, this may 
confer a survival benefit.  
Even in the subgroup of more severe airflow limitation (GOLD group 3 & 4), 
the significant difference noted in the change in RVM or RVMI in the allopurinol 
group compared to the placebo group was not accompanied by a significance 
difference in the change in NT-proBNP level between the two groups.  
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It is probably safer to say that allopurinol did not have any effects on NT-
proBNP levels in patients with pulmonary hypertension associated with chronic 
lung disease. This would be in line with the results of previous studies173,174 
where a significant change in ventricular mass was observed without a change 
in NT-proBNP level. 
Cardiac troponins are cardiac biomarkers. Concentrations of cardiac troponins 
do not increase unless myocyte damage has occurred. High-sensitivity cardiac 
troponins are powerful predictors of long-term mortality and cardiovascular 
disease in the general population.215 
The baseline levels of high-sensitive troponin I (hs-Trop I) were similar in both 
allopurinol (3.22 pg/ml) and placebo (3.59 pg/ml) groups. The level of hs-Trop 
I increased in the placebo group (+0.18 pg/ml) and slightly reduced in the 
allopurinol group (-0.20 pg/ml). The difference in the change in hs-Trop I levels 
was not significant. This also raised the possibility that allopurinol may have 
some beneficial effects on the heart but the study was unable to prove that as 
it was not powered for change in blood markers. A possible explanation for the 
above finding is the improvement in cardiac energetics as mentioned in the 
previous section. 
As expected, the serum uric acid level was reduced from baseline by 







4.3.4 Health related questionnaires 
The St George Respiratory Questionnaire (SGRQ) is the most relevant quality 
of life questionnaire for this cohort of patients with chronic lung disease. There 
was no significant difference in the change in SGRQ total score between the 
allopurinol and the placebo group. This did not change when looking at SGRQ 
subdomains, i.e. symptom score, activity score and impact score. In addition, 
the change in SGRQ total score from baseline did not reach the minimal 
clinically important difference of 4 unit change in this study.  
When looking at SF-36 which is a general quality of life measure questionnaire, 
there were also no significant differences in the change in all nine domains of 
the questionnaire between the allopurinol and the placebo group.  
These results probably reflect the overall absence of beneficial effect of 
allopurinol in the studied population. Subgroup analyses like the ones done for 
the primary outcome did not change the results. 
It is interesting that there was a statistically significant reduction in right 
ventricular mass in the subgroup of patients with more severe airflow limitation 
but no significant change in health related questionnaire scores in the same 
subgroup. This probably means that a change in ventricular mass may not 
translate into a change in quality of life. Obviously here, it is difficult to make 
this a definite conclusion. Further studies looking at this subgroup would help 
to clarify this. 
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In contrast, a statistically significant difference was observed in the TDI score 
between allopurinol (-0.7 ± 0.9) and placebo (-0.1 ± 0.9). This finding needs to 
be interpreted cautiously as only 54 of 63 completed cases (86%) were used 
for the analysis of TDI scores. It is difficult to explain the significant finding 
above when allopurinol did not have an overall impact on the primary outcome 
and the other secondary outcomes (including other quality of life questionnaire 
scores). The TDI score did not reach the 1-unit change from baseline in either 
group which is considered to be the minimal clinically important difference in 
clinical trials.195 This statistically significant finding is not clinically significant 
and therefore, it would be wise to conclude that allopurinol is unlikely to be of 












All the spirometric measurements and ratios (i.e FEV1, FEV1 %, FVC, FVC % 
and FEV1/FVC, FEF25-75 and FEF25-75 %) were similar at baseline in both 
allopurinol and placebo groups. After 12 months of treatment, there was no 
significant difference in the change in the measurements between the two 
groups. There was also no significant change from the baseline values in both 
groups. These results are comparable to Ichinose et al.182 study which 
demonstrated no change in FEV1 after 10 patients with COPD was treated with 































4.4 Strengths & Limitations 
Both participants and investigators were blind to treatment. All cardiac MRI 
measurements were performed by a single investigator (JWM), eliminating 
inter-observer variability. There was similar number of withdrawals in both 
allopurinol and placebo groups (see CONSORT diagram, Figure 21). The total 
number of withdrawals was as predicted and the study was appropriately 
powered for the primary outcome measure.  
One of the limitations of this study is that right heart catheterisation (RHC), 
which is the gold standard for assessing pulmonary haemodynaemics, was not 
done. RHC is invasive and it would introduce unnecessary risk and reduce the 
number of patients willing to be recruited, hence potentially making recruits 
atypical. Pulmonary acceleration time (PAT) is a good alternative and non-
invasive echo measurement that has a correlation coefficient of r = 0.88 with 
pulmonary pressures.216 
Another limitation is the lack of data on transfer factor of the lung for carbon 
monoxide. Transfer factor is a measure of the extent to which oxygen diffuses 
from the lungs into the blood stream. Reduction in transfer factor is very 
common in chronic lung disease due to the structural lung abnormalities. 
Pulmonary hypertension causes a further reduction in the transfer factor. If the 
transfer factor was measured, it would have helped to further characterise the 
study population. However, it was not an essential parameter as it was not 
expected that allopurinol would have any beneficial effect on transfer factor. 
188 
 
Post-hoc analyses of data are fraught with limitations. They conform to neither 
the population nor the randomisation model of statistical inference, which is 
the foundaton of randomised clinical trials.217 The results from post-hoc 
analyses should be interpreted carefully as they might have been nothing more 
















In conclusion, there was no overall effect of high dose allopurinol on right 
ventricular hypertrophy in patients with pulmonary hypertension associated 
with chronic obstructive pulmonary disease or interstitial lung disease. There 
was also no overall effect of allopurinol on LV and RV measurements (by 
CMRI), on quality of life questionnaires, spirometry, six-minute walk test and 
blood markers. 
There was a potential benefit of allopurinol in COPD patients with more severe 
airflow limitation (FEV1 < 50% predicted). There was also a potential benefit of 
allopurinol in patients with higher NT-proBNP levels. Further studies are 











4.6 Future research 
A study involving patients with a more strict criteria of at least severe airflow 
limitation would be the logical next step. The primary outcome would still be 
regression of right ventricular hypertrophy. This is because the aim of treating 
patients with pulmonary hypertension is to prevent progression of right 
ventricular hypertrophy to ventricular dilatation, and eventually to ventricular 
failure. The study would involve a treatment period of 24 months with repeating 
the outcome measures at half-way (that is, at 12 months). A longer duration of 
treatment may help to unmask whether ventricular regression may confer 













1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for 
the diagnosis and treatment of pulmonary hypertension: The Joint Task Force 
for the Diagnosis and Treatment of Pulmonary Hypertension of the European 
Society of Cardiology (ESC) and the European Respiratory Society (ERS): 
Endorsed by: Association for European Paediatric and Congenital Cardiology 
(AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur 
Respir J 2015; 46(4): 903-75. 
2. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical 
classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62(25 
Suppl): D34-41. 
3. Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial flutter and 
fibrillation in patients with pulmonary hypertension. Int J Cardiol 2013; 167(5): 
2300-5. 
4. Trip P, Nossent EJ, de Man FS, et al. Severely reduced diffusion 
capacity in idiopathic pulmonary arterial hypertension: patient characteristics 
and treatment responses. Eur Respir J 2013; 42(6): 1575-85. 
5. Bradlow WM, Hughes ML, Keenan NG, et al. Measuring the heart in 
pulmonary arterial hypertension (PAH): implications for trial study size. J Magn 
Reson Imaging 2010; 31(1): 117-24. 
192 
 
6. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ. 
Interstudy reproducibility of right ventricular volumes, function, and mass with 
cardiovascular magnetic resonance. Am Heart J 2004; 147(2): 218-23. 
7. Peacock AJ, Vonk Noordegraaf A. Cardiac magnetic resonance 
imaging in pulmonary arterial hypertension. Eur Respir Rev 2013; 22(130): 
526-34. 
8. Seeger W, Adir Y, Barbera JA, et al. Pulmonary hypertension in chronic 
lung diseases. J Am Coll Cardiol 2013; 62(25 Suppl): D109-16. 
9. Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in 
COPD: results from the ASPIRE registry. Eur Respir J 2013; 41(6): 1292-301. 
10. Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic 
factors in COPD patients receiving long-term oxygen therapy. Importance of 
pulmonary artery pressure. Chest 1995; 107(5): 1193-8. 
11. Kessler R, Faller M, Weitzenblum E, et al. "Natural history" of 
pulmonary hypertension in a series of 131 patients with chronic obstructive 
lung disease. Am J Respir Crit Care Med 2001; 164(2): 219-24. 
12. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence 
and outcomes of pulmonary arterial hypertension in advanced idiopathic 
pulmonary fibrosis. Chest 2006; 129(3): 746-52. 
193 
 
13. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in 
advanced COPD candidates for lung volume reduction surgery or lung 
transplantation. Chest 2005; 127(5): 1531-6. 
14. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary 
hypertension and chronic obstructive pulmonary disease. Am J Respir Crit 
Care Med 2005; 172(2): 189-94. 
15. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary 
disease: current burden and future projections. Eur Respir J 2006; 27(2): 397-
412. 
16. Bronchitis MRCCotAoC. Definition and classification of chronic 
bronchitis for clinical and epidemiological purposes. A report to the Medical 
Research Council by their Committee on the Aetiology of Chronic Bronchitis. 
Lancet 1965; 1(7389): 775-9. 
17. Tan WC, Lo C, Jong A, et al. Marijuana and chronic obstructive lung 
disease: a population-based study. Cmaj 2009; 180(8): 814-20. 
18. Zhou Y, Zou Y, Li X, et al. Lung function and incidence of chronic 
obstructive pulmonary disease after improved cooking fuels and kitchen 




19. Paulin LM, Diette GB, Blanc PD, et al. Occupational exposures are 
associated with worse morbidity in patients with chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med 2015; 191(5): 557-65. 
20. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a 
reversible factor in the prognosis of chronic obstructive pulmonary disease. 
Am J Respir Crit Care Med 1998; 157(6 Pt 1): 1791-7. 
21. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the 
Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 
2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med 2017; 
195(5): 557-82. 
22. Decramer M, Janssens W. Chronic obstructive pulmonary disease and 
comorbidities. Lancet Respir Med 2013; 1(1): 73-83. 
23. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters 
EF. Systemic effects of smoking. Chest 2007; 131(5): 1557-66. 
24. Zangiabadi A, De Pasquale CG, Sajkov D. Pulmonary hypertension and 
right heart dysfunction in chronic lung disease. Biomed Res Int 2014; 2014: 
739674. 
25. Leopold JG, Gough J. The centrilobular form of hypertrophic 
emphysema and its relation to chronic bronchitis. Thorax 1957; 12(3): 219-35. 
195 
 
26. Stone IS, Barnes NC, Petersen SE. Chronic obstructive pulmonary 
disease: a modifiable risk factor for cardiovascular disease? Heart 2012; 
98(14): 1055-62. 
27. Shino MY, Lynch JP, 3rd, Saggar R, Abtin F, Belperio JA. Pulmonary 
hypertension complicating interstitial lung disease and COPD. Semin Respir 
Crit Care Med 2013; 34(5): 600-19. 
28. Wrobel JP, Thompson BR, Williams TJ. Mechanisms of pulmonary 
hypertension in chronic obstructive pulmonary disease: a pathophysiologic 
review. J Heart Lung Transplant 2012; 31(6): 557-64. 
29. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: 
epidemiology, significance, and management: pulmonary vascular disease: 
the global perspective. Chest 2010; 137(6 Suppl): 39s-51s. 
30. Hales CA. The site and mechanism of oxygen sensing for the 
pulmonary vessels. Chest 1985; 88(4 Suppl): 235s-40s. 
31. Steiner MK. World Health Organization Class III COPD-associated 
pulmonary hypertension: are we there yet in understanding the pathobiology 
of the disease? Chest 2009; 136(3): 658-9. 
32. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary 




33. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in 
pulmonary hypertension. Circulation 2004; 109(2): 159-65. 
34. Dinh-Xuan AT, Higenbottam TW, Clelland CA, et al. Impairment of 
endothelium-dependent pulmonary-artery relaxation in chronic obstructive 
lung disease. N Engl J Med 1991; 324(22): 1539-47. 
35. Barbera JA, Peinado VI, Santos S, Ramirez J, Roca J, Rodriguez-
Roisin R. Reduced expression of endothelial nitric oxide synthase in 
pulmonary arteries of smokers. Am J Respir Crit Care Med 2001; 164(4): 709-
13. 
36. Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic 
obstructive pulmonary disease: current theories of pathogenesis and their 
implications for treatment. Thorax 2005; 60(7): 605-9. 
37. Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow 
obstruction, and impaired left ventricular filling. N Engl J Med 2010; 362(3): 
217-27. 
38. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. 
Predictive factors of hospitalization for acute exacerbation in a series of 64 
patients with chronic obstructive pulmonary disease. Am J Respir Crit Care 
Med 1999; 159(1): 158-64. 
197 
 
39. Sims MW, Margolis DJ, Localio AR, Panettieri RA, Kawut SM, Christie 
JD. Impact of pulmonary artery pressure on exercise function in severe COPD. 
Chest 2009; 136(2): 412-9. 
40. Chen X, Tang S, Liu K, et al. Therapy in stable chronic obstructive 
pulmonary disease patients with pulmonary hypertension: a systematic review 
and meta-analysis. J Thorac Dis 2015; 7(3): 309-19. 
41. American Thoracic Society/European Respiratory Society International 
Multidisciplinary Consensus Classification of the Idiopathic Interstitial 
Pneumonias. This joint statement of the American Thoracic Society (ATS), and 
the European Respiratory Society (ERS) was adopted by the ATS board of 
directors, June 2001 and by the ERS Executive Committee, June 2001. Am J 
Respir Crit Care Med 2002; 165(2): 277-304. 
42. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic 
Society/European Respiratory Society statement: Update of the international 
multidisciplinary classification of the idiopathic interstitial pneumonias. Am J 
Respir Crit Care Med 2013; 188(6): 733-48. 
43. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur 
Respir J 2008; 31(6): 1357-67. 
44. Panagiotou M, Church AC, Johnson MK, Peacock AJ. Pulmonary 




45. Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. 
Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin 
Proc 2007; 82(3): 342-50. 
46. Caminati A, Cassandro R, Harari S. Pulmonary hypertension in chronic 
interstitial lung diseases. Eur Respir Rev 2013; 22(129): 292-301. 
47. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary 
hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur 
Respir J 2007; 30(4): 715-21. 
48. Minai OA, Santacruz JF, Alster JM, Budev MM, McCarthy K. Impact of 
pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis. 
Respir Med 2012; 106(11): 1613-21. 
49. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and 
pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 
2007; 175(9): 875-80. 
50. Strange C, Highland KB. Pulmonary hypertension in interstitial lung 
disease. Curr Opin Pulm Med 2005; 11(5): 452-5. 
51. Cantin AM, North SL, Fells GA, Hubbard RC, Crystal RG. Oxidant-
mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 
1987; 79(6): 1665-73. 
52. Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. 
Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing 
199 
 
alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J 
Respir Crit Care Med 1997; 156(6): 1897-901. 
53. Iwasawa T, Kato S, Ogura T, et al. Low-normal lung volume correlates 
with pulmonary hypertension in fibrotic idiopathic interstitial pneumonia: 
computer-aided 3D quantitative analysis of chest CT. AJR Am J Roentgenol 
2014; 203(2): W166-73. 
54. Shekerdemian L, Bohn D. Cardiovascular effects of mechanical 
ventilation. Arch Dis Child 1999; 80(5): 475-80. 
55. Farkas L, Farkas D, Ask K, et al. VEGF ameliorates pulmonary 
hypertension through inhibition of endothelial apoptosis in experimental lung 
fibrosis in rats. J Clin Invest 2009; 119(5): 1298-311. 
56. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. 
Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing 
alveolitis. Lancet 1993; 341(8860): 1550-4. 
57. Uguccioni M, Pulsatelli L, Grigolo B, et al. Endothelin-1 in idiopathic 
pulmonary fibrosis. J Clin Pathol 1995; 48(4): 330-4. 
58. Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial 
pressure and diffusion capacity of the lung as prognosticator in patients with 
idiopathic pulmonary fibrosis. Chest 2007; 131(3): 650-6. 
200 
 
59. Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide 
and exercise capacity in lung fibrosis and pulmonary hypertension. Am J 
Respir Crit Care Med 2004; 170(4): 360-5. 
60. Group NOTT. Continuous or nocturnal oxygen therapy in hypoxemic 
chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy 
Trial Group. Ann Intern Med 1980; 93(3): 391-8. 
61. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. 
Long-term oxygen therapy can reverse the progression of pulmonary 
hypertension in patients with chronic obstructive pulmonary disease. Am Rev 
Respir Dis 1985; 131(4): 493-8. 
62. Barbera JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-
Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in 
chronic obstructive pulmonary disease. Lancet 1996; 347(8999): 436-40. 
63. Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange 
effects of sildenafil in patients with chronic obstructive pulmonary disease and 
pulmonary hypertension. Am J Respir Crit Care Med 2010; 181(3): 270-8. 
64. Blanco I, Santos S, Gea J, et al. Sildenafil to improve respiratory 
rehabilitation outcomes in COPD: a controlled trial. Eur Respir J 2013; 42(4): 
982-92. 
65. Goudie AR, Lipworth BJ, Hopkinson PJ, Wei L, Struthers AD. Tadalafil 
in patients with chronic obstructive pulmonary disease: a randomised, double-
201 
 
blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2014; 2(4): 
293-300. 
66. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of 
lung fibrosis and pulmonary hypertension: a randomised controlled trial. 
Lancet 2002; 360(9337): 895-900. 
67. Han MK, Bach DS, Hagan PG, et al. Sildenafil preserves exercise 
capacity in patients with idiopathic pulmonary fibrosis and right-sided 
ventricular dysfunction. Chest 2013; 143(6): 1699-708. 
68. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves 
walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131(3): 897-9. 
69. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, 
Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic 
pulmonary fibrosis. N Engl J Med 2010; 363(7): 620-8. 
70. Valerio G, Bracciale P, Grazia D'Agostino A. Effect of bosentan upon 
pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv 
Respir Dis 2009; 3(1): 15-21. 
71. Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of 
bosentan in severe COPD. Eur Respir J 2008; 32(3): 619-28. 
72. Corte TJ, Keir GJ, Dimopoulos K, et al. Bosentan in pulmonary 
hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J 
Respir Crit Care Med 2014; 190(2): 208-17. 
202 
 
73. King TE, Jr., Brown KK, Raghu G, et al. BUILD-3: a randomized, 
controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit 
Care Med 2011; 184(1): 92-9. 
74. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary 
fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 
158(9): 641-9. 
75. Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J. 
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised 
controlled MUSIC trial. Eur Respir J 2013; 42(6): 1622-32. 
76. Saadjian A, Philip-Joet F, Paganelli F, Arnaud A, Levy S. Long-term 
effects of cicletanine on secondary pulmonary hypertension. J Cardiovasc 
Pharmacol 1998; 31(3): 364-71. 
77. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and 
iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J 
Respir Crit Care Med 1999; 160(2): 600-7. 
78. Saggar R, Khanna D, Vaidya A, et al. Changes in right heart 
haemodynamics and echocardiographic function in an advanced phenotype of 
pulmonary hypertension and right heart dysfunction associated with 
pulmonary fibrosis. Thorax 2014; 69(2): 123-9. 
203 
 
79. Simonneau G, Escourrou P, Duroux P, Lockhart A. Inhibition of hypoxic 
pulmonary vasoconstriction by nifedipine. N Engl J Med 1981; 304(26): 1582-
5. 
80. Morrell NW, Higham MA, Phillips PG, Shakur BH, Robinson PJ, 
Beddoes RJ. Pilot study of losartan for pulmonary hypertension in chronic 
obstructive pulmonary disease. Respir Res 2005; 6: 88. 
81. Ghofrani HA, Staehler G, Grunig E, et al. Acute effects of riociguat in 
borderline or manifest pulmonary hypertension associated with chronic 
obstructive pulmonary disease. Pulm Circ 2015; 5(2): 296-304. 
82. Hoeper MM, Halank M, Wilkens H, et al. Riociguat for interstitial lung 
disease and pulmonary hypertension: a pilot trial. Eur Respir J 2013; 41(4): 
853-60. 
83. Han MK, McLaughlin VV, Criner GJ, Martinez FJ. Pulmonary diseases 
and the heart. Circulation 2007; 116(25): 2992-3005. 
84. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function 
and failure: report of a National Heart, Lung, and Blood Institute working group 
on cellular and molecular mechanisms of right heart failure.  Circulation. United 
States; 2006: 1883-91. 
85. Pinsky MR. The right ventricle: interaction with the pulmonary 
circulation. Critical care (London, England) 2016; 20: 266. 
204 
 
86. Vonk Noordegraaf A, Westerhof BE, Westerhof N. The Relationship 
Between the Right Ventricle and its Load in Pulmonary Hypertension. J Am 
Coll Cardiol 2017; 69(2): 236-43. 
87. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right 
ventricle under pressure: cellular and molecular mechanisms of right-heart 
failure in pulmonary hypertension. Chest 2009; 135(3): 794-804. 
88. Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR. 
Pathobiology of pulmonary arterial hypertension and right ventricular failure. 
The European respiratory journal 2012; 40(6): 1555-65. 
89. Vonk-Noordegraaf A, Marcus JT, Holverda S, Roseboom B, Postmus 
PE. Early changes of cardiac structure and function in COPD patients with mild 
hypoxemia. Chest 2005; 127(6): 1898-903. 
90. Scott KW. A clinicopathological study of fatal chronic airways 
obstruction. Thorax 1976; 31(6): 693-701. 
91. Takimoto E, Kass DA. Role of Oxidative Stress in Cardiac Hypertrophy 
and Remodeling. Hypertension (Dallas, Tex : 1979) 2007. 
92. Hsia CC. Cardiopulmonary limitations to exercise in restrictive lung 
disease. Med Sci Sports Exerc 1999; 31(1 Suppl): S28-32. 
93. van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right 
ventricular mass, volume, and function in idiopathic pulmonary arterial 
hypertension. European heart journal 2007; 28(10): 1250-7. 
205 
 
94. van de Veerdonk MC, Bogaard HJ, Voelkel NF. The right ventricle and 
pulmonary hypertension. Heart failure reviews 2016; 21(3): 259-71. 
95. Gorter TM, Verschuuren EA, van Veldhuisen DJ, et al. Right ventricular 
recovery after bilateral lung transplantation for pulmonary arterial 
hypertensiondagger. Interactive cardiovascular and thoracic surgery 2017. 
96. Reesink HJ, Marcus JT, Tulevski, II, et al. Reverse right ventricular 
remodeling after pulmonary endarterectomy in patients with chronic 
thromboembolic pulmonary hypertension: utility of magnetic resonance 
imaging to demonstrate restoration of the right ventricle. The Journal of 
thoracic and cardiovascular surgery 2007; 133(1): 58-64. 
97. Kirkham PA, Barnes PJ. Oxidative stress in COPD. Chest 2013; 144(1): 
266-73. 
98. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of 
ageing. Nature 2000; 408(6809): 239-47. 
99. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role 
of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 
2002; 34(4): 379-88. 
100. Battelli MG, Polito L, Bortolotti M, Bolognesi A. Xanthine 
Oxidoreductase-Derived Reactive Species: Physiological and Pathological 
Effects. Oxidative medicine and cellular longevity 2016; 2016: 3527579. 
206 
 
101. Harrison R. Structure and function of xanthine oxidoreductase: where 
are we now? Free radical biology & medicine 2002; 33(6): 774-97. 
102. Pritsos CA. Cellular distribution, metabolism and regulation of the 
xanthine oxidoreductase enzyme system. Chemico-biological interactions 
2000; 129(1-2): 195-208. 
103. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular 
disease: molecular mechanisms and pathophysiological implications. The 
Journal of physiology 2004; 555(Pt 3): 589-606. 
104. Kelley EE, Hock T, Khoo NK, et al. Moderate hypoxia induces xanthine 
oxidoreductase activity in arterial endothelial cells. Free radical biology & 
medicine 2006; 40(6): 952-9. 
105. Poss WB, Huecksteadt TP, Panus PC, Freeman BA, Hoidal JR. 
Regulation of xanthine dehydrogenase and xanthine oxidase activity by 
hypoxia. The American journal of physiology 1996; 270(6 Pt 1): L941-6. 
106. Hassoun PM, Yu FS, Shedd AL, et al. Regulation of endothelial cell 
xanthine dehydrogenase xanthine oxidase gene expression by oxygen 
tension. The American journal of physiology 1994; 266(2 Pt 1): L163-71. 
107. Kahl S, Elsasser TH. Endotoxin challenge increases xanthine oxidase 
activity in cattle: effect of growth hormone and vitamin E treatment. Domestic 
animal endocrinology 2004; 26(4): 315-28. 
207 
 
108. Faggioni R, Gatti S, Demitri MT, et al. Role of xanthine oxidase and 
reactive oxygen intermediates in LPS- and TNF-induced pulmonary edema. 
The Journal of laboratory and clinical medicine 1994; 123(3): 394-9. 
109. Page S, Powell D, Benboubetra M, et al. Xanthine oxidoreductase in 
human mammary epithelial cells: activation in response to inflammatory 
cytokines. Biochimica et biophysica acta 1998; 1381(2): 191-202. 
110. Wright RM, Ginger LA, Kosila N, et al. Mononuclear phagocyte xanthine 
oxidoreductase contributes to cytokine-induced acute lung injury. American 
journal of respiratory cell and molecular biology 2004; 30(4): 479-90. 
111. Pfeffer KD, Huecksteadt TP, Hoidal JR. Xanthine dehydrogenase and 
xanthine oxidase activity and gene expression in renal epithelial cells. Cytokine 
and steroid regulation. Journal of immunology (Baltimore, Md : 1950) 1994; 
153(4): 1789-97. 
112. Terada LS, Guidot DM, Leff JA, et al. Hypoxia injures endothelial cells 
by increasing endogenous xanthine oxidase activity. Proc Natl Acad Sci U S 
A 1992; 89(8): 3362-6. 
113. Panus PC, Wright SA, Chumley PH, Radi R, Freeman BA. The 
contribution of vascular endothelial xanthine dehydrogenase/oxidase to 




114. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine 
oxidase inhibitors: renaissance half a century after the discovery of allopurinol. 
Pharmacol Rev 2006; 58(1): 87-114. 
115. Battelli MG, Bolognesi A, Polito L. Pathophysiology of circulating 
xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. 
Biochimica et biophysica acta 2014; 1842(9): 1502-17. 
116. Meneshian A, Bulkley GB. The physiology of endothelial xanthine 
oxidase: from urate catabolism to reperfusion injury to inflammatory signal 
transduction. Microcirculation (New York, NY : 1994) 2002; 9(3): 161-75. 
117. Kelley EE, Khoo NK, Hundley NJ, Malik UZ, Freeman BA, Tarpey MM. 
Hydrogen peroxide is the major oxidant product of xanthine oxidase. Free 
radical biology & medicine 2010; 48(4): 493-8. 
118. Aggarwal S, Gross CM, Sharma S, Fineman JR, Black SM. Reactive 
oxygen species in pulmonary vascular remodeling. Compr Physiol 2013; 3(3): 
1011-34. 
119. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin 
Invest 2005; 115(3): 500-8. 
120. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy 
and remodeling. Hypertension 2007; 49(2): 241-8. 
209 
 
121. Abdulnour RE, Peng X, Finigan JH, et al. Mechanical stress activates 
xanthine oxidoreductase through MAP kinase-dependent pathways. Am J 
Physiol Lung Cell Mol Physiol 2006; 291(3): L345-53. 
122. Reddy S, Bernstein D. Molecular Mechanisms of Right Ventricular 
Failure. Circulation 2015; 132(18): 1734-42. 
123. Wang X, Shults NV, Suzuki YJ. Oxidative profiling of the failing right 
heart in rats with pulmonary hypertension. PLoS One 2017; 12(5): e0176887. 
124. Gagliardi AC, Miname MH, Santos RD. Uric acid: A marker of increased 
cardiovascular risk. Atherosclerosis 2009; 202(1): 11-7. 
125. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk 
of major coronary heart disease events. Heart 1997; 78(2): 147-53. 
126. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N 
Engl J Med 2008; 359(17): 1811-21. 
127. Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM. Impact of 
allopurinol use on urate concentration and cardiovascular outcome. Br J Clin 
Pharmacol 2011; 71(4): 600-7. 
128. Kadowaki T, Hamada H, Yokoyama A, et al. Significance of serum uric 
acid in patients with chronic respiratory failure treated with non-invasive 
positive pressure ventilation. Intern Med 2007; 46(11): 691-7. 
210 
 
129. Garcia-Pachon E, Padilla-Navas I, Shum C. Serum uric acid to 
creatinine ratio in patients with chronic obstructive pulmonary disease. Lung 
2007; 185(1): 21-4. 
130. Nagaya N, Uematsu M, Satoh T, et al. Serum uric acid levels correlate 
with the severity and the mortality of primary pulmonary hypertension. Am J 
Respir Crit Care Med 1999; 160(2): 487-92. 
131. Rundles RW. The development of allopurinol. Arch Intern Med 1985; 
145(8): 1492-503. 
132. Graham S, Day RO, Wong H, et al. Pharmacodynamics of oxypurinol 
after administration of allopurinol to healthy subjects. Br J Clin Pharmacol 
1996; 41(4): 299-304. 
133. Elion EB, Callahan SW, Hitchings GH, Rundles RW, Laszlo J. 
Experimental, clinical, and metabolic studies of thiopurines. Cancer 
Chemother Rep 1962; 16: 197-202. 
134. Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams 
KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and 
oxypurinol. Clin Pharmacokinet 2007; 46(8): 623-44. 
135. Galbusera C, Orth P, Fedida D, Spector T. Superoxide radical 
production by allopurinol and xanthine oxidase. Biochemical pharmacology 
2006; 71(12): 1747-52. 
211 
 
136. Turnheim K, Krivanek P, Oberbauer R. Pharmacokinetics and 
pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin 
Pharmacol 1999; 48(4): 501-9. 
137. Lartigue-Mattei C, Chabard JL, Ristori JM, et al. Kinetics of allopurinol 
and its metabolite oxypurinol after oral administration of allopurinol alone or 
associated with benzbromarone in man. Simultaneous assay of hypoxanthine 
and xanthine by gas chromatography-mass spectrometry. Fundam Clin 
Pharmacol 1991; 5(7): 621-33. 
138. Bianchi R, Vitali C, Clerico A, et al. Uric acid metabolism in normal 
subjects and in gouty patients by chromatographic measurement of 14C-uric 
acid in plasma and urine. Metabolism 1979; 28(11): 1105-13. 
139. Elion GB, Yu TF, Gutman AB, Hitchings GH. Renal clearance of 
oxipurinol, the chief metabolite of allopurinol. Am J Med 1968; 45(1): 69-77. 
140. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. 
Description and guidelines for prevention in patients with renal insufficiency. 
Am J Med 1984; 76(1): 47-56. 
141. George J, Struthers AD. The role of urate and xanthine oxidase 
inhibitors in cardiovascular disease. Cardiovasc Ther 2008; 26(1): 59-64. 
142. McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to 
allopurinol in hospitalised patients. Ann Rheum Dis 1981; 40(3): 245-9. 
212 
 
143. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most 
common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis 
in Europe and Israel. J Am Acad Dermatol 2008; 58(1): 25-32. 
144. Johnson WD, Kayser KL, Brenowitz JB, Saedi SF. A randomized 
controlled trial of allopurinol in coronary bypass surgery. American heart 
journal 1991; 121(1 Pt 1): 20-4. 
145. Rashid MA, William-Olsson G. Influence of allopurinol on cardiac 
complications in open heart operations. The Annals of thoracic surgery 1991; 
52(1): 127-30. 
146. Taggart DP, Young V, Hooper J, et al. Lack of cardioprotective efficacy 
of allopurinol in coronary artery surgery. Br Heart J 1994; 71(2): 177-81. 
147. Coetzee A, Roussouw G, Macgregor L. Failure of allopurinol to improve 
left ventricular stroke work after cardiopulmonary bypass surgery. J 
Cardiothorac Vasc Anesth 1996; 10(5): 627-33. 
148. Hadi HA, Carr CS, Al Suwaidi J. Endothelial Dysfunction: 
Cardiovascular Risk Factors, Therapy, and Outcome. Vasc Health Risk Manag 
2005; 1(3): 183-98. 
149. Guthikonda S, Sinkey C, Barenz T, Haynes WG. Xanthine oxidase 




150. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol 
normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. 
Hypertension 2000; 35(3): 746-51. 
151. Kao MP, Ang DS, Gandy SJ, et al. Allopurinol benefits left ventricular 
mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 
2011; 22(7): 1382-9. 
152. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol 
improves endothelial dysfunction in chronic heart failure. Circulation 2002; 
106(2): 221-6. 
153. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine 
oxidase inhibition with allopurinol on endothelial function and peripheral blood 
flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-
controlled studies. Circulation 2002; 105(22): 2619-24. 
154. Rajendra NS, Ireland S, George J, Belch JJ, Lang CC, Struthers AD. 
Mechanistic insights into the therapeutic use of high-dose allopurinol in angina 
pectoris. J Am Coll Cardiol 2011; 58(8): 820-8. 
155. El Solh AA, Saliba R, Bosinski T, Grant BJ, Berbary E, Miller N. 
Allopurinol improves endothelial function in sleep apnoea: a randomised 
controlled study. Eur Respir J 2006; 27(5): 997-1002. 
156. Mackenzie IS, Ford I, Walker A, et al. Multicentre, prospective, 
randomised, open-label, blinded end point trial of the efficacy of allopurinol 
214 
 
therapy in improving cardiovascular outcomes in patients with ischaemic heart 
disease: protocol of the ALL-HEART study. BMJ Open 2016; 6(9): e013774. 
157. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol 
improves endothelial function by profoundly reducing vascular oxidative stress 
and not by lowering uric acid. Circulation 2006; 114(23): 2508-16. 
158. Ekelund UE, Harrison RW, Shokek O, et al. Intravenous allopurinol 
decreases myocardial oxygen consumption and increases mechanical 
efficiency in dogs with pacing-induced heart failure. Circ Res 1999; 85(5): 437-
45. 
159. Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves 
myocardial efficiency in patients with idiopathic dilated cardiomyopathy. 
Circulation 2001; 104(20): 2407-11. 
160. Hirsch GA, Bottomley PA, Gerstenblith G, Weiss RG. Allopurinol 
acutely increases adenosine triphospate energy delivery in failing human 
hearts. J Am Coll Cardiol 2012; 59(9): 802-8. 
161. Opie LH. Allopurinol for heart failure: novel mechanisms.  J Am Coll 
Cardiol. United States; 2012: 809-12. 
162. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, 
MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic 
heart failure: a retrospective cohort study. Heart 2002; 87(3): 229-34. 
215 
 
163. Wei L, Fahey T, Struthers AD, MacDonald TM. Association between 
allopurinol and mortality in heart failure patients: a long-term follow-up study. 
Int J Clin Pract 2009; 63(9): 1327-33. 
164. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide 
concentrations and haemoglobin but does not alter exercise capacity in 
chronic heart failure. Heart 2005; 91(6): 749-53. 
165. Shehab AM, Butler R, MacFadyen RJ, Struthers AD. A placebo-
controlled study examining the effect of allopurinol on heart rate variability and 
dysrhythmia counts in chronic heart failure. Br J Clin Pharmacol 2001; 51(4): 
329-34. 
166. Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with 
symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 
2008; 51(24): 2301-9. 
167. Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of Xanthine 
Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine 
Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) 
Study. Circulation 2015; 131(20): 1763-71. 
168. Rentoukas E, Tsarouhas K, Tsitsimpikou C, Lazaros G, Deftereos S, 
Vavetsi S. The prognostic impact of allopurinol in patients with acute 
myocardial infarction undergoing primary percutaneous coronary intervention. 
Int J Cardiol 2010; 145(2): 257-8. 
216 
 
169. Separham A, Ghaffari S, Najafi H, Ghaffari R, Ziaee M, Babaei H. The 
Impact of Allopurinol on Patients With Acute ST Elevation Myocardial Infarction 
Undergoing Thrombolytic Therapy. J Cardiovasc Pharmacol 2016; 68(4): 265-
8. 
170. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-
dose allopurinol on exercise in patients with chronic stable angina: a 
randomised, placebo controlled crossover trial. Lancet 2010; 375(9732): 2161-
7. 
171. de Abajo FJ, Gil MJ, Rodriguez A, et al. Allopurinol use and risk of non-
fatal acute myocardial infarction. Heart 2015; 101(9): 679-85. 
172. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic 
implications of echocardiographically determined left ventricular mass in the 
Framingham Heart Study. N Engl J Med 1990; 322(22): 1561-6. 
173. Rekhraj S, Gandy SJ, Szwejkowski BR, et al. High-dose allopurinol 
reduces left ventricular mass in patients with ischemic heart disease. J Am Coll 
Cardiol 2013; 61(9): 926-32. 
174. Szwejkowski BR, Gandy SJ, Rekhraj S, et al. Allopurinol reduces left 
ventricular mass in patients with type 2 diabetes and left ventricular 
hypertrophy. J Am Coll Cardiol 2013; 62(24): 2284-93. 
217 
 
175. Boueiz A, Damarla M, Hassoun PM. Xanthine oxidoreductase in 
respiratory and cardiovascular disorders. Am J Physiol Lung Cell Mol Physiol 
2008; 294(5): L830-40. 
176. Hoshikawa Y, Ono S, Suzuki S, et al. Generation of oxidative stress 
contributes to the development of pulmonary hypertension induced by 
hypoxia. J Appl Physiol (1985) 2001; 90(4): 1299-306. 
177. Dopp JM, Philippi NR, Marcus NJ, et al. Xanthine oxidase inhibition 
attenuates endothelial dysfunction caused by chronic intermittent hypoxia in 
rats. Respiration 2011; 82(5): 458-67. 
178. Williams AL, Chen L, Scharf SM. Effects of allopurinol on cardiac 
function and oxidant stress in chronic intermittent hypoxia. Sleep Breath 2010; 
14(1): 51-7. 
179. Jankov RP, Kantores C, Pan J, Belik J. Contribution of xanthine 
oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in 
neonatal rats. Am J Physiol Lung Cell Mol Physiol 2008; 294(2): L233-45. 
180. Pinamonti S, Muzzoli M, Chicca MC, et al. Xanthine oxidase activity in 
bronchoalveolar lavage fluid from patients with chronic obstructive pulmonary 
disease. Free Radic Biol Med 1996; 21(2): 147-55. 
181. Komaki Y, Sugiura H, Koarai A, et al. Cytokine-mediated xanthine 
oxidase upregulation in chronic obstructive pulmonary disease's airways. Pulm 
Pharmacol Ther 2005; 18(4): 297-302. 
218 
 
182. Ichinose M, Sugiura H, Yamagata S, et al. Xanthine oxidase inhibition 
reduces reactive nitrogen species production in COPD airways. Eur Respir J 
2003; 22(3): 457-61. 
183. Heunks LM, Vina J, van Herwaarden CL, Folgering HT, Gimeno A, 
Dekhuijzen PN. Xanthine oxidase is involved in exercise-induced oxidative 
stress in chronic obstructive pulmonary disease. Am J Physiol 1999; 277(6 Pt 
2): R1697-704. 
184. Zharikov SI, Swenson ER, Lanaspa M, Block ER, Patel JM, Johnson 
RJ. Could uric acid be a modifiable risk factor in subjects with pulmonary 
hypertension? Med Hypotheses 2010; 74(6): 1069-74. 
185. Kjaeve J, Veel T, Bjertnaes L. Allopurinol inhibits hypoxic pulmonary 
vasoconstriction. Role of toxic oxygen metabolites. Acta Anaesthesiol Scand 
1990; 34(5): 384-8. 
186. Primary Care | NHS Research Scotland | NHS Research Scotland. 
2017. https://www.nhsresearchscotland.org.uk/research-areas/primary-care. 
187. Health Research Scotland | NHS Research Scotland | Register for 
Share. 2017. https://www.registerforshare.org/. 
188. Ferrazza A, Marino B, Giusti V, Affinito V, Ragonese P. Usefulness of 
left and right oblique subcostal view in the echo-Doppler investigation of 
pulmonary arterial blood flow in patients with chronic obstructive pulmonary 
219 
 
disease. The subxiphoid view in the echo-Doppler evaluation of pulmonary 
blood flow. Chest 1990; 98(2): 286-9. 
189. Dabestani A, Mahan G, Gardin JM, et al. Evaluation of pulmonary artery 
pressure and resistance by pulsed Doppler echocardiography. Am J Cardiol 
1987; 59(6): 662-8. 
190. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of 
spirometry. The European respiratory journal 2005; 26(2): 319-38. 
191. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit 
Care Med 2002; 166(1): 111-7. 
192. Sciurba F, Criner GJ, Lee SM, et al. Six-minute walk distance in chronic 
obstructive pulmonary disease: reproducibility and effect of walking course 
layout and length. Am J Respir Crit Care Med 2003; 167(11): 1522-7. 
193. Desikan R, Mason HL, Rupp MT, Skehan M. Health-related quality of 
life and healthcare resource utilization by COPD patients: a comparison of 
three instruments. Quality of life research : an international journal of quality of 
life aspects of treatment, care and rehabilitation 2002; 11(8): 739-51. 
194. Rutten-van Molken M, Roos B, Van Noord JA. An empirical comparison 
of the St George's Respiratory Questionnaire (SGRQ) and the Chronic 
Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax 
1999; 54(11): 995-1003. 
220 
 
195. Witek TJ, Jr., Mahler DA. Minimal important difference of the transition 
dyspnoea index in a multinational clinical trial. Eur Respir J 2003; 21(2): 267-
72. 
196. Sato S, Nishimura K, Tsukino M, et al. Possible maximal change in the 
SF-36 of outpatients with chronic obstructive pulmonary disease and asthma. 
The Journal of asthma : official journal of the Association for the Care of 
Asthma 2004; 41(3): 355-65. 
197. Stahl E, Lindberg A, Jansson SA, et al. Health-related quality of life is 
related to COPD disease severity. Health and quality of life outcomes 2005; 3: 
56. 
198. Verrill D, Barton C, Beasley W, Lippard WM. The effects of short-term 
and long-term pulmonary rehabilitation on functional capacity, perceived 
dyspnea, and quality of life. Chest 2005; 128(2): 673-83. 
199. Patel AS, Siegert RJ, Keir GJ, et al. The minimal important difference 
of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced 
vital capacity in interstitial lung disease. Respiratory medicine 2013; 107(9): 
1438-43. 
200. Patel AS, Siegert RJ, Brignall K, et al. The development and validation 
of the King's Brief Interstitial Lung Disease (K-BILD) health status 
questionnaire. Thorax 2012; 67(9): 804-10. 
221 
 
201. RD M. Simplified calculation of body-surface area. N Engl J Med 1987; 
317(17): 1098. 
202. Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and 
treatment of pulmonary arterial hypertension. Circulation 2008; 118(11): 1195-
201. 
203. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin 
Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J 
Respir Crit Care Med 2005; 171(11): 1292-7. 
204. Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER, et al. Normal 
values for cardiovascular magnetic resonance in adults and children. J 
Cardiovasc Magn Reson 2015; 17: 29. 
205. van Wolferen SA, Boonstra A, Marcus JT, et al. Right ventricular 
reverse remodelling after sildenafil in pulmonary arterial hypertension. Heart 
2006; 92(12): 1860-1. 
206. Peacock AJ, Crawley S, McLure L, et al. Changes in right ventricular 
function measured by cardiac magnetic resonance imaging in patients 
receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR 
study. Circ Cardiovasc Imaging 2014; 7(1): 107-14. 
207. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with 
oral sildenafil is safe and improves functional capacity and hemodynamics in 
222 
 
patients with pulmonary arterial hypertension. Circulation 2003; 108(17): 2066-
9. 
208. Roeleveld RJ, Vonk-Noordegraaf A, Marcus JT, et al. Effects of 
epoprostenol on right ventricular hypertrophy and dilatation in pulmonary 
hypertension. Chest 2004; 125(2): 572-9. 
209. van de Veerdonk MC, Huis In TVAE, Marcus JT, et al. Upfront 
combination therapy reduces right ventricular volumes in pulmonary arterial 
hypertension. Eur Respir J 2017; 49(6). 
210. Hohlfeld JM, Vogel-Claussen J, Biller H, et al. Effect of lung deflation 
with indacaterol plus glycopyrronium on ventricular filling in patients with 
hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, 
placebo-controlled, single-centre trial. Lancet Respir Med 2018; 6(5): 368-78. 
211. Stone IS, Barnes NC, James WY, et al. Lung Deflation and 
Cardiovascular Structure and Function in Chronic Obstructive Pulmonary 
Disease. A Randomized Controlled Trial. Am J Respir Crit Care Med 2016; 
193(7): 717-26. 
212. Mainguy V, Malenfant S, Neyron AS, et al. Alternatives to the six-minute 
walk test in pulmonary arterial hypertension. PLoS One 2014; 9(8): e103626. 
213. Mainguy V, Malenfant S, Neyron AS, et al. Repeatability and 
responsiveness of exercise tests in pulmonary arterial hypertension. Eur 
Respir J 2013; 42(2): 425-34. 
223 
 
214. Ulrich S, Fischler M, Speich R, Bloch KE. Wrist actigraphy predicts 
outcome in patients with pulmonary hypertension. Respiration 2013; 86(1): 45-
51. 
215. Holzmann MJ. Clinical implications of high-sensitivity cardiac troponins. 
J Intern Med 2018; 284(1): 50-60. 
216. Kiely DG, Cargill RI, Wheeldon NM, Coutie WJ, Lipworth BJ. 
Haemodynamic and endocrine effects of type 1 angiotensin II receptor 
blockade in patients with hypoxaemic cor pulmonale. Cardiovasc Res 1997; 
33(1): 201-8. 
217. Curran-Everett D, Milgrom H. Post-hoc data analysis: benefits and 






































































































































































Appendix J - Case report form (CRF) 
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